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ABSTRACT 
 
 Background information on the epidemiology of atrial fibrillation (AF), including 
descriptive data and risk factors, pathophysiology, clinical aspects and outcomes, as well 
as three original manuscripts that together form the basis of this doctoral dissertation, are 
presented. The objectives of this dissertation were to assess temporal trends in the 
occurrence and prognosis of AF among acute myocardial infarction (MI) patients, to 
determine the usefulness of administrative data to identify incident AF, and to describe 
the impact of AF on healthcare utilization. 
 AF in the setting of MI occurs frequently and is associated with increased 
mortality. Nonetheless, temporal trends in the occurrence of AF complicating MI and in 
the prognosis of these patients are not well described. In a population-based sample of 
20,049 validated first incident nonfatal hospitalized MIs from the Atherosclerosis Risk in 
Communities (ARIC) Study, prevalence of AF in MI increased from 11% to 15% 
(adjusted odds ratio [OR] for prevalent AF: 1.11; 95% confidence interval [CI]: 1.04 – 
1.19 per five-year increment) from 1987 through 2009. In patients with MI, AF was 
associated with increased 1-year mortality (adjusted OR 1.47, 95% CI 1.07-2.01) 
compared to those without AF. However, there was no evidence that the impact of AF on 
MI survival changed over time or differed over time by sex, race or MI classification. In 
the setting of MI, co-occurrence of AF should be considered a critical clinical event and 
treatment needs unique to this population should be explored further. 
  iv 
Increasingly, epidemiologic studies use administrative data to identify AF. 
Capture of incident AF is not well documented. ARIC cohort participants without 
prevalent AF enrolled in fee-for-service Medicare, Parts A and B, for at least 12 
continuous months between 1991 and 2009 were included. Of 10,134 eligible 
participants, 738 developed AF according to both ARIC and Centers for Medicare and 
Medicaid Services (CMS); an additional 93 and 288 incident cases were identified using 
only ARIC and CMS data, respectively. Incidence rates per 1,000 person-years were 10.8 
(95% CI: 10.1–11.6) and 13.6 (95% CI: 12.8–14.4) in ARIC and CMS, respectively; 
agreement was 96%; the kappa statistic was 0.77 (95% CI: 0.75–0.80). Additional CMS 
events did not alter observed associations between risk factors and AF. Drawbacks of 
CMS are its inapplicability to those <65 years and inability to capture AF for those with 
Medicare Advantage. 
AF is associated with increased risk of hospitalizations. However, little is known 
about the impact of AF on non-inpatient healthcare utilization or about sex or race 
differences in AF-related utilization. ARIC cohort participants with incident AF (n=944) 
enrolled in fee-for-service Medicare, Parts A and B, for at least 12 continuous months 
between 1991 and 2009 were matched on age, sex, race and center to up to three 
participants without AF (n=2,761). The average annual days hospitalized were 13.1 (95% 
CI: 11.5-15.0) and 2.8 (95% CI: 2.5-3.1) for those with and without AF, respectively; the 
annual numbers of outpatient claims were 53.2 (95% CI: 50.4-56.1) and 23.0 (95% CI: 
22.2-23.8) for those with and without AF, respectively. Most utilization in AF patients 
was attributable to non-AF conditions, particularly other- cardiovascular disease-related 
  v 
reasons. There was suggestive evidence that sex modified the association between AF 
and inpatient utilization, with AF related to greater utilization in women than men. The 
association between AF and healthcare utilization was similar in whites and blacks. In 
addition to rate or rhythm treatment, management of AF also should focus on the 
accompanying cardiovascular comorbidities.  
Overall, the results from this dissertation indicate that co-occurrence of AF in MI 
is a critical clinical event, that administrative data can be useful in AF epidemiologic 
research, and AF patients have substantial healthcare utilization, especially for other-
cardiovascular disease-related reasons. 
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2.0 INTRODUCTION 
 
Atrial fibrillation (AF) was first reported to affect humans in 1906 when two 
publications reported that “auricular fibrillation” was common in heart disease patients 
and that it could be identified by a new instrument, the electrocardiograph.
1
 Subsequent 
to its discovery, AF has become the most common sustained cardiac arrhythmia; the 
estimated prevalence in the United States (US) in 2010 was between 2.7 and 6.1 million 
and it is expected to increase to between 5.6 and 12 million by 2050.
2,3
 Overall, 
prevalence is 1% in the general adult population but increases dramatically with age from 
less than 1% among those less than 60 years of age to 9% among octogenarians.
2,4
 A 
number of important risk factors for developing AF have been identified and include 
advancing age,
2,5,6
 male sex,
3,5
 white race,
7
 hypertension,
5,8
 diabetes,
9,10
 obesity,
11
 
metabolic syndrome,
12
 hyperthyroidism,
13
 acute myocardial infarction (MI),
5,14
 heart 
failure (HF),
5,15
 valvular heart disease,
5
 sleep apnea
16,17
 and structural cardiac 
abnormalities.
5
 AF is a major cause of morbidity, especially stroke,
18,19
 HF,
20,21
 acute 
MI
22,23
 and dementia
24,25
 as well as mortality.
15,26,27
 The primary treatment objectives are 
correction of rhythm disturbance, prevention of thromboembolism and heart rate 
control.
28
 However, the preferred treatment strategy has yet to be determined.
29
 
Healthcare costs associated with AF are substantial. The total incremental cost of AF in 
the first year after diagnosis in the US in 2008 dollars was $26 billion, of which $6 billion 
was attributed to AF.
30
 AF is a major public health concern as it is associated with 
significant morbidity and mortality as well as with substantial healthcare costs. The 
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burden of AF is expected to increase, as AF is increasing in prevalence, due in part to the 
aging population and increasing prevalence of chronic heart disease. 
  3     3 
3.0 DESCRIPTIVE EPIDEMIOLOGY 
 
3.1 INCIDENCE AND PREVALENCE 
 AF is the most common sustained cardiac arrhythmia. Both the incidence and 
prevalence of AF have been increasing steadily. In 2010 AF affected between 2.7 and 6.1 
million Americans; the prevalence is estimated to increase to between 5.6 and 12.1 
million by 2050.
2,3,31
 The lifetime risk of developing AF among whites is one in four.
32
 
Among blacks the lifetime risk is lower; at age 80, one in nine will develop AF.
7
  
 Several population-based cohort studies have estimated the incidence of AF. In 
Olmsted County, Minnesota, a predominately white population, the age- and sex-adjusted 
incidence of AF per 1,000 person-years increased from 3.04 (95% confidence interval 
[CI]: 2.78 – 3.31) in 1980 to 3.68 (95% CI: 3.42 – 3.95) in 2000 or a significant relative 
increase of 12.6% (95% CI: 2.1 – 23.1), p = 0.014.3 Age is a particularly strong risk 
factor for AF and the Cardiovascular Health Study (CHS), a population-based study 
among adults aged ≥ 65 years, calculated an AF incidence rate of 19.2 per 1,000 person-
years.
8
 Onset of AF was strongly associated with age, male sex and cardiovascular 
disease (CVD); the incidence rate per 1,000 person-years among men aged 65 – 74 and 
75 – 84 was 17.6 and 42.7, respectively, and the corresponding rates for women were 
10.1 and 21.6, respectively.
8
 The Atherosclerosis Risk in Communities (ARIC) study 
found that, compared to whites, blacks had a 41% (95% CI: 8% - 62%) lower age- and 
sex-adjusted risk of being diagnosed with AF.
7
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In addition to utilizing cohort studies to determine AF incidence, administrative 
data from Medicare have been used. In the Medicare population, those 65 years and 
older, the age- and sex-adjusted incidence rate of AF per 1,000 person-years was virtually 
unchanged from 1993 to 2007 at 27.3 and 28.3, respectively.
27
 Similarly to population-
based studies, incidence increased substantially with age and men and whites had 
consistently higher rates.
27
     
 There is an increasing prevalence of AF; advancing age, male sex and white race 
are associated with prevalent AF.
2
 The prevalence of AF increases dramatically with age 
from 0.1% among adults < 55 years of age to 9.0% among those 80 years and older.
2
 In 
the CHS 4.8% of women and 6.2% of men had AF at baseline.
14
 The prevalence varied 
based on presence of CVD; the prevalence among those with clinical, subclinical and no 
evidence of CVD was 9.1%, 4.6% and 1.6%, respectively.
14
 In the Framingham Heart 
Study (FHS) the age-adjusted prevalence from 1968-1970 to 1987-1989 increased from 
3.2% to 9.1% among men and from 2.8% to 4.7% among women.
33
  
 Administrative data from Medicare indicate that the prevalence of AF has 
increased during the last several decades.
27,34
 From 2003-2007 there was a 5% mean 
annual increase in prevalence; as of 2007, 85.8 per 1,000 Medicare beneficiaries had 
AF.
27
 The magnitude of the increase was greatest among the oldest beneficiaries, those 
age 90 and older.
27
 Based on data from the National Hospital Discharge Survey, 
hospitalizations for AF as the principle diagnosis increased 144.3% from 1985 to 1999; 
during this same time span, hospitalizations with any mention of AF increased 189.9%.
35
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From 1996-2001 there was a 34% increase in hospitalizations with AF as the primary 
diagnosis.
36
 
Globally AF incidence and prevalence are increasing. Among Canadians, 
Europeans and Australians the incidence and prevalence are similar to the US.
15,37-40
 The 
majority of published epidemiological studies have been conducted in predominately 
white populations in North America and Europe. However, there is a growing body of 
literature in nonwhite populations.
41
 In Asian countries the incidence of AF is fairly 
similar; in Taiwan the incidence rate per 1,000 person-years in men and women was 0.76 
and 1.68, respectively; in Japan the incidence rate was 2.2 per 1,000 person-years.
41
 The 
prevalence of AF has been found to vary markedly between countries; in India the 
prevalence is very low at 0.1%, while in Japan the prevalence consistently ranges from 
0.6% - 1.6%. Prevalence estimates in Japan are similar to those in Taiwan and Thailand.
41
 
Among Chinese living in Singapore, the prevalence of AF among those 80 and older is 
about half that observed in Western populations at 5.8%.
42
 Few studies in South America 
have examined the incidence and/or prevalence of AF. A population-based study in Sao 
Paulo, Brazil, found 2.4% of the population 65 years and older had AF.
43
 There is a 
shortage of studies in Africa and they are almost exclusively hospital-based, where 
prevalence is expected to be higher. In one recent study, 4.6% of cardiac patients that 
presented at the hospital had AF.
44
 As in the US, risk factors for AF include increasing 
age, male sex and hypertension.
15,38,39,41
 
 
3.2 MORTALITY 
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The risk of death among those with first-detected AF is particularly high during 
the months immediately following diagnosis. Among residents of Olmsted County, 
Minnesota, the age- and sex-matched hazard ratios (HR) for mortality among those with 
new-onset AF compared to those without AF were 9.62 (95% CI: 8.93 – 10.32) in the 
first four months and 1.66 (95% CI: 1.59 – 1.73) subsequently.45 In the FHS the 
multivariable adjusted odds ratio (OR) for death among those with AF compared to those 
without AF was of 1.5 (95% CI: 1.2 – 1.8) in men and 1.9 (95% CI: 1.5 – 2.2) in 
women.
26
 In addition, there was a significant age-sex interaction and AF was found to 
abate the female survival advantage.
26
 The Women’s Health Study (WHS) corroborated 
these findings.
46
 From 1980 to 2000 there was no trend in the age-, sex- and calendar year 
of diagnosis adjusted mortality.
45
 
Hospital-based and administrative data are increasingly utilized to determine 
mortality following AF diagnosis. Among Medicare beneficiaries mortality following an 
AF diagnosis is 3.5 times higher than expected; 30-day and one-year mortality are 12.6% 
and 27.6%, respectively.
27
 Hospital-based data have found no significant change in in-
hospital mortality.
36
 However, death certificate data indicate that deaths due to AF have 
been on the rise. The age-standardized mortality rate for AF, as the underlying or 
contributory cause of death, per 100,000 people increased from 27.6 in 1980 to 69.8 in 
1998.
47
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4.0 RISK FACTORS 
 
4.1 DEMOGRAPHIC 
 Demographic characteristics, including age, sex and race/ethnicity, are known to 
be associated with AF. Age is perhaps the most important nonmodifiable risk factor for 
AF. The incidence of AF doubles with each decade of life (Figure 4.1).
5
 Consequently 
the prevalence of AF increases from 0.5% to 9% among 50-59 and 80-89 year olds, 
respectively.
4
 As a result of the dramatic increase in AF incidence with advancing age, 
the lifetime risk of AF at 40 and 80 years is stable, approximately one in four.
32
 The 
median age of patients with AF is 75.
48,49
 About 70% of AF patients are between 65 and 
85 years of age.
49
  
 
Figure 4.1: Incidence of atrial fibrillation by age in two cohort studies. Framingham = 
Framing Heart Study; CHS = Cardiovascular Health Study. From Fuster V, et al. 
Circulation. 2006;114(7):e257-354.  
 Male sex consistently has been associated with increased risk of developing 
AF.
3,5,7,8
 Men had a 1.5-fold higher risk (95% CI: 1.3 – 1.8; p-value <0.0001) of 
developing AF than women, after adjustment for age and other risk factors, in the FHS.
5
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In Olmsted County, Minnesota, the incidence ratio for men compared to women was 
1.86.
3
 The overall and age-specific prevalence of AF is higher in men than in women.
2
 
However, the prevalence is high among both men and women at older ages.
2,49
 In the 
CHS, among 65 – 69 year olds, AF prevalence was higher among men than women; 
however, among 70-79 year olds, the prevalence was indistinguishable.
14
 
The majority of epidemiologic data on AF in the US is based on whites. Despite 
limited data on racial/ethnic differences, there is evidence that differences do exist. In the 
US, the burden of AF is lower among blacks even though they have a higher prevalence 
of risk factors for AF.
12,50
 The age- and sex-adjusted incidence of AF in blacks was 41% 
lower (95% CI: 8% - 62%) compared to whites in the ARIC study.
7
 The prevalence of 
AF among adults aged 50 and older was also significantly lower in blacks compared to 
whites in the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) study.
2
  A 
recent study sought to determine the role of genetic ancestry in the development of AF 
among blacks. European ancestry was a significant predictor of incident AF. After 
adjustment for potential confounders, every 10% increase in European ancestry increased 
the risk of incident AF by 17% (95% CI: 1.07 – 1.29; p<0.001).51  
 
4.2 BEHAVIORAL 
 The role of dietary habits, including alcohol and n-3 polyunsaturated fatty acid 
(PUFA) consumption, in the development of AF has been studied. Episodic heavy 
alcohol consumption, coined “holiday heart,” long has been known to be associated with 
the onset of AF.
52
 Heavy alcohol consumption impacts maintenance of sinus rhythm 
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through several mechanisms, including electrophysiological changes in atrial cells,
53,54
 
direct impact on myocardial structure,
55
 impaired vagal tone
56
 and achievement of a 
hyperadrenergic state.
57
 Habitual consumption of low to moderate amounts of alcohol are 
not thought to be associated with AF.
58-61
 The FHS found an increased risk of AF among 
those who consumed more than 36 grams of alcohol/day (about three drinks/day) but no 
association at lower levels.
61
 The CHS found no association between current moderate 
alcohol consumption and development of AF.
58
 Despite these results, a recent meta-
analysis reported a pooled estimate of 1.08 (95% CI: 1.05-1.10) for each 10 gram per day 
increment of alcohol.
62
 In this analysis, a linear model showed a significant association 
between alcohol consumption and AF and there was no evidence of a J-shaped 
association or threshold effect.
62
 Nevertheless, low to moderate alcohol consumption is 
not thought to increase the risk of AF.
62,63
     
The association between fish-derived n-3 PUFAs and incident AF is unclear. The 
CHS found a protective effect of n-3 PUFAs; consumption of tuna or other broiled or 
baked fish, but not fried fish or fish sandwiches, was associated with a lower incidence of 
AF.
64
 After adjustment for confounders, consumption of tuna or other broiled or baked 
fish 1-4 times per week and ≥5 times per week was associated with a 28% (95% CI: 0.58 
– 0.91) and 31% (95% CI: 0.52-0.91) lower risk of incident AF, respectively, compared 
to consumption <1 time per month (p trend = 0.004).
64
 However, five other large 
prospective cohort studies found no association.
65-69
 There are several potential 
explanations for the inconsistent results, including that a larger proportion of the CHS 
participants consumed high amounts of fish compared to the other studies and total fish 
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consumption (fried, baked, broiled) was combined in some studies and fried fish may 
have adverse effects. Despite inconsistent results, there are biological mechanisms that 
support an inverse association between n-3 PUFAs and AF; n-3 PUFAs are protective 
against coronary heart disease
70,71
 and might play a role in preventing inflammatory 
triggers from initiating ectopic activity resulting in AF.
72
 
 In addition to dietary habits, behaviors that might affect the development of AF 
have been studied, including exercise. Numerous studies have reported an increased risk 
of AF, particularly lone AF, among vigorous exercisers and elite athletes.
73-77
 Among 
elderly adults, ≥65 years, exercise intensity had a U-shaped association with AF 
(interaction term p = 0.02); light to moderate physical activity was associated with a 
reduced risk of AF.
78
 However, in a middle-aged population, there was no association 
between work related physical activity and risk of AF.
79
 In the WHS, increasing quintiles 
of physical activity were associated with reduced risk of AF (HR for extreme quintiles: 
0.82; 95% CI: 0.66 – 1.01; p trend = 0.007). The association was attenuated after 
adjustment for body mass index (BMI) (HR for extreme quintiles: 0.99; 95% CI: 0.80 – 
1.23; p trend = 0.22).
80
   
Smoking is another behavior that increases the risk of coronary heart disease 
(CHD) but the association with AF is uncertain. Smoking affects several mechanisms 
involved in the etiology of AF;
81
 smoking increases oxidative stress,
82
 inflammation
82
 
and atrial fibrosis.
83
 In ARIC, the multivariable-adjusted HRs for AF were 1.32 (95% CI: 
1.10 – 1.57) in former smokers, 1.58 (95% CI: 1.35 – 1.85) in ever smokers and 2.05 
(95% CI: 1.71 – 2.47) in current smokers, compared to never smokers.84 These results 
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corroborate earlier findings in the Rotterdam Study
85
 and the Manitoba Follow-Up 
Study.
15
 In the FHS, smoking increased the odds of developing AF among women but not 
men,
5
 while two other large population-based studies found no association.
86,87
  
 
4.3 TRADITIONAL CARDIOVASCULAR DISEASE 
 Of the traditional CVD risk factors, hypertension is consistently one of the most 
important contributors to the burden of AF. There is a linear trend in the association 
between increasing systolic and diastolic blood pressure and increasing AF risk.
88
 
Similarly, in the CHS, a positive association was reported; for each 10 mm Hg increment 
in systolic blood pressure, an 11% increased risk of AF was reported.
8
 In the FHS, the 
multivariable adjusted OR for new-onset AF among hypertensive men and women was 
1.5 (95% CI: 1.2 – 2.0) and 1.4 (95% CI: 1.1 – 1.8), respectively.5 In ARIC, the 
population attributable fraction (%) for elevated blood pressure (systolic blood pressure ≥ 
140 mm Hg, diastolic blood pressure ≥ 90 mm Hg, or antihypertensive medication) was 
21.6% (95% CI: 16.8% – 26.7%).70 
 The association of type-2 diabetes mellitus and new-onset AF is inconsistent. A 
recent meta-analysis reported that patients with diabetes mellitus had a 34% greater risk 
of new-onset AF compared to non-diabetics (95% CI: 1.07 – 1.68) after correcting for 
publication bias.
10
 Results from the ARIC study corroborate the meta-analysis; compared 
to non-diabetics, having type-2 diabetes mellitus was associated with a 35% increased 
risk of new-onset AF (95% CI: 1.14 – 1.60) after adjustment for confounders.9 
Additionally, in those with and without diabetes, there was a positive linear association 
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between HbA1c and the risk of AF.
9
 However, other studies have found no association.
89-
91
 The mechanisms by which increased glucose levels and diabetes mellitus promote a 
proarrhythmic effect are not fully understood. Insulin resistance, a mechanism involved 
in the association of both hypertension and obesity with AF, is thought to play an 
important role.
92
 Long-term inflammation has been suggested as a mediator in the link 
between diabetes mellitus and AF; higher levels of C-reactive protein, interleukin-6 and 
other inflammatory markers are found in atrial biopsies of patients with AF.
93,94
 
 Obesity consistently has been associated with an increased risk of developing AF. 
Five population-based cohort studies included in a meta-analysis each reported a 
significantly increased risk of AF among obese participants. The pooled results indicated 
a 49% increased risk (95% CI: 1.36 – 1.64) of developing AF in obese compared to 
nonobese adults.
11
 There was a positive graded association between BMI and increased 
AF risk; compared to normal weight participants, overweight and obese participants had 
a 39% and 87% increased risk, respectively.
11
 Obesity and overweight accounted for 
17.9% of all incident AF cases in the ARIC study.
70
 Despite the consistent association, 
the mechanisms by which obesity increases the risk of AF are not fully understood. 
Obesity often clusters with other risk factors for AF, such as hypertension, diabetes and 
obstructive sleep apnea (OSA), all of which increase the risk of AF.
16,95,96
 Obesity might 
act as an indirect cause through hemodynamic (increased heart rate, blood pressure and 
stroke volume) and/or metabolic changes.
96-98
 Additionally, left ventricular hypertrophy 
with subsequent atrial dilation may have a role in the development of AF.
97
  
  13     13 
 While the clinical significance of metabolic syndrome as an entity has not been 
firmly established, research has found an association between this disorder and 
development of AF. Metabolic syndrome is defined as the clustering of three or more of 
the following: elevated blood pressure, abdominal obesity, impaired glucose tolerance, 
low high-density lipoprotein cholesterol and elevated triglycerides.
99
 In a prospective 
community-based cohort in Japan, there was a 61% increased risk of AF among 
individuals with metabolic syndrome (95% CI: 1.21 – 2.15; p = 0.001).100 Each 
component of the metabolic syndrome, except elevated triglycerides, increased the risk of 
incident AF.
100
 Another smaller study in Japan corroborates these results.
101
 In ARIC, 
participants with, compared to those without, metabolic syndrome had a 67% increased 
risk of incident AF (95% CI: 1.49 – 1.87).12 Once again, elevated blood pressure, 
abdominal obesity, impaired glucose tolerance and low high-density lipoprotein 
cholesterol, but not elevated triglycerides, were independently associated with an 
increased risk of AF (Table 4.1).
12
 Additionally, there was a monotonically increased risk 
of AF with the increasing number of metabolic syndrome components present (5 
components versus 0 components: HR: 4.40; 95% CI: 3.25 – 5.94).12 The mechanisms 
underlying the association between metabolic syndrome and AF are likely due to the 
pathophysiological effects that occur as a result of each individual component of 
metabolic syndrome as well as the cumulative effect that might increase the risk of AF 
through development of CHD or HF. 
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Table 4.1: Overall and race-specific hazard ratios and 95% confidence intervals for atrial 
fibrillation by the individual components of the metabolic syndrome and by number of 
components fulfilled, ARIC 1987-2005. From Chamberlain AM, et al. Am Heart J. 
2010;159(5):850-856.  
Over the past decade accumulating evidence indicates that inflammation is 
involved in the initiation and maintenance of AF.
102,103
 Inflammatory markers were 
known to be elevated in AF patients, but it was unclear if inflammation was a cause or a 
consequence of AF.
93
 However, in CHS, C-reactive protein (CRP) was found to be 
associated with the presence of AF at baseline and with incidence of AF. Among 
participants with AF at baseline, the prevalence of AF was significantly higher among 
those in the highest quartile of CRP compared to the lowest.
104
 Furthermore, the risk of 
incident AF was 31% greater in participants in the highest CRP quartile compared to the 
lowest (95% CI: 1.08 – 1.58; p = 0.005).104  
 
4.4 MAJOR COMORBIDITIES 
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 Individuals with major cardiovascular comorbidities, such as acute MI, HF and 
valvular heart disease, are at an increased risk of developing AF. In the FHS, history of 
MI was associated with a multivariable adjusted OR of developing AF of 1.4 (95% CI: 
1.0 – 2.0; p < 0.05) and 1.2 (95% CI: 0.8 – 1.8) in men and women, respectively.5 Other 
population-based cohort studies have found similar increased risk.
14,15
 HF is consistently 
associated with an increased risk of new-onset AF.
5,14,15
 Among men, the odds of 
developing AF were 4.5 times greater (95% CI: 3.1 – 6.6; p < 0.0001) in those with 
concomitant HF compared to those without; among women, the odds were 5.9 times 
greater (95% CI: 4.2 – 8.4; P < 0.0001).5 Women were significantly more likely to have 
valvular heart disease,
5
 but the associated increased risk of developing AF occurred 
among both men and women.
14,15
 In the Manitoba Follow-Up Study, the risk of incident 
AF was significantly higher among those with a history of MI (HR: 3.62; 95% CI: 2.59 – 
5.07), HF (HR: 3.37; 95% CI:2.29 – 4.96) and valvular heart disease (HR: 3.15; 95% CI: 
1.99 – 5.00).15 In addition to increasing risk on a population level, each of these comorbid 
conditions is predicative of a person’s individual risk of developing AF.6,105 AF following 
cardiac surgery is a common complication and the incidence has increased continuously 
over the past decades.
106
 The incidence of post-operative AF is about 30% following 
coronary artery bypass grafting.
106,107
 The incidence is even higher after valve 
replacement or repair at 40% and nearly 50% following combined procedures.
106
  
In addition to cardiovascular comorbidities, there are several noncardiovascular 
conditions that have a strong association with development of AF, including OSA, 
reduced lung function and hyperthyroidism. OSA is highly prevalent in AF patients. 
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Among AF patients undergoing electrocardioversion, 49% had OSA compared with 32% 
of general cardiology patients (p = 0.0004).
108
 The multivariable-adjusted odds of AF 
were four times higher in patients with sleep-disordered breathing compared to those 
without sleep-disordered breathing (95% CI: 1.03 – 15.74).17 In a retrospective cohort 
study, OSA was an independent predictor of incident AF among individuals <65 years of 
age but not among older adults.
16
 The association was independent of the effect of 
obesity on risk of AF.
16
 A case-crossover design was utilized to determine if an apnea 
episode acts as a trigger for paroxysmal AF. While the absolute rate of AF associated 
with respiratory disturbances was low, the odds of AF after a respiratory disturbance 
were nearly 18 times higher than (95% CI: 5.3 – 58.4) the odds of AF after normal 
breathing.
109
 Among AF patients who had cardioversion, recurrence of AF at one year 
was nearly double among those not using continuous positive airway pressure (CPAP) 
therapy compared to those using CPAP (p = 0.01).
110
  
The few studies that have examined the association of forced expiratory volume 
in one second (FEV1) with AF development report contradictory results. The 
multivariable adjusted OR of incident AF among individuals with a FEV1 between 60-
80% compared to those with a normal FEV1 (≥ 80%) was 1.8 (95% CI: 1.01 – 3.05).
111
 
However, results from the multivariable adjusted analysis in the FHS indicate that FEV1 
is not an independent predictor of AF.
5
 Case-control studies have found that AF patients 
have a higher prevalence of reduced lung function than control patients, irrespective of 
risk factors.
112,113
 The mechanisms that connect reduced lung function and AF have not 
been clearly elucidated, but there are several potential explanations including ectopic 
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beats originating in the pulmonary veins, deterioration of the blood gas composition, 
hypoxia, hemodynamic changes due to pulmonary hypertension, stress on the right 
atrium and inflammation.
114,115
 
Clinical and subclinical hyperthyroidism are established risk factors for AF. In a 
recent meta-analysis, subclinical hyperthyroidism was associated with a 71% increased 
risk of incident AF (95% CI: 1.18 – 2.48) compared to euthyroidism, after multivariable 
adjustment.
13
 There was an inverse association between thyrotropin level and AF; 
compared to 0.45 – 4.99 mIU/L (normal) the multivariable adjusted risk of AF was 1.70 
(95% CI: 1.15 – 2.53) and 2.34 (95% CI: 0.98 – 5.58) with thyrotropin levels of 0.10 – 
0.44 mIU/L (subclinical) and <0.10 mIU/L (clinical), respectively (p trend = 0.06).
13
 
Individual studies not included in the meta-analysis found similar associations.
116-119
 In 
totality, the data indicate there is a graded inverse association.   
 
4.5 STRUCTURAL CARDIAC ABNORMALITIES 
 Structural cardiac abnormalities often are found in patients with AF, but the 
echocardiographic precursors of AF were unknown until the FHS report in 1994 (Table 
4.2).
120
 After adjustment for age, sex and other risk factors, left atrial size, left ventricular 
fractional shortening and the sum of septal and left ventricular posterior wall thickness 
were independent echocardiographic predictors of AF (Table 4.2).
4,120
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Table 4.2: Multivariable adjusted hazard ratios for echocardiographic variables 
significantly associated with risk of atrial fibrillation. From Vaziri SM, et al. Circulation. 
Feb 1994;89(2):724-730. 
Left ventricular diastolic dysfunction is independently predictive of AF. There is a 
graded association of risk based on the severity of diastolic dysfunction.
121
 Additionally, 
there is some evidence that mitral annular calcification is associated with risk of 
developing AF.
50,120
 
 
4.6 GENETIC PREDISPOSITION 
In the past decade, a genetic component to AF in the general population has been 
established.
122-124
 In the FHS, having at least one parent with AF was associated with a 
1.85-fold higher odds of AF in the adult offspring (95% CI: 1.12 – 2.06; p = 0.02).122 
Also from the FHS, after multivariable adjustment, the risk of incident AF was greater if 
the first-degree relative’s age of onset was ≤ 65 years (HR: 2.01; 95% CI: 1.49 – 2.71; p 
< 0.001).
125
 The risk of new-onset AF increased by 24% for each additional affected first-
degree relative (95% CI: 1.05 – 1.46; p = 0.01).125 In a large study of Icelanders, the risk 
of developing AF, compared to the general population, was nearly double among those 
with a first-degree relative with AF; in patients diagnosed with AF before age 60, the risk 
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among first-degree relatives was almost fivefold greater.
124
 Mutations in sodium and 
potassium gene coding channels, somatic myocardial mutations in gap junction proteins 
and signaling alterations have been identified in lone AF or familial AF series. However, 
they are not a major contributor to AF in the community.
126
  
Recent genome-wide association studies have identified several single-nucleotide 
polymorphisms (SNPs) associated with AF. Two sequence variants on chromosome 4q25 
had a strong association with AF. These variants are adjacent, upstream, of the PITX2 
gene, which has a critical function in left-right asymmetry of the heart.
127
 SNP rs2106261 
on chromosome 16q22, which is near gene ZFHX3, was significantly associated with AF 
in a meta-analysis of five community-based cohort studies and replicated in an 
independent cohort.
128
 ZFHX3 is thought to regulate myogenic and neuronal 
differentiation; however, the role in cardiac tissue is not known.
128
 The causative SNPs 
and the functional basis of these associations are still under investigation.  A GWAS 
among individuals of European descent corroborated previously identified susceptibility 
loci on chromosomes 4q25 and ZFHX3 and identified six new AF susceptibility loci.
129
 
SNP rs3903239 on chromosome 1q24 in PRRX1, which encodes a homeodomain 
transcription factor that is highly expressed in the developing heart, especially in 
connective tissue, was the most significant new association.
129
 Other susceptibility loci 
included chromosome 7q31, SNP rs3807989, in CAV1; chromosome 14q23, rs1152591 
located in an intron of SYNE2; chromosome 9q22, rs10821415 located in an ORF on 
chromosome 9; chromosome 15q24 rs7164883, in the first intron of HCN4 and 
chromosome 10q22 rs10824026 located 5 kb upstream of SYNPO2L and 20 kb upstream 
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of MYOZ1.
129
 These loci are located on genes that encode transcription factors related to 
cardiopulmonary development, cardiac-expressed ion channels and cell signaling 
molecules.
129
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5.0 PATHOPHYSIOLOGY 
 
5.1 NATURAL HISTORY 
 AF is an uncoordinated atrial tachyarrhythmia caused by rapid and irregular atrial 
depolarization which results in ineffective atrial contraction.
130,131
 AF is characterized by 
the absence of distinct P-waves before each QRS complex, the presence of rapid atrial 
oscillations (F-waves) and variable RR intervals on electrocardiogram (ECG).
131
 
Initiation of AF requires a trigger and, in order for AF to persist, the trigger must remain 
or electrical remodeling that promotes AF in the absence of the trigger must occur.
28,131
  
Underlying atrial pathology can result in AF. Atrial fibrosis and loss of atrial 
muscle mass are the most common pathoanatomic changes.
28,132
 Atrial fibrosis can be 
triggered by many factors including inflammation
133
 and atrial dilation caused by any 
type of CVD associated with AF, including hypertension, HF and atherosclerosis.
134
 
Histological changes also have been identified. Heterogeneity of conduction is caused, at 
least in part, by fibrotic atrial fibers juxtaposed with healthy atrial tissue.
135
 In addition to 
atrial pathology resulting in AF, AF causes numerous changes in the atrial architecture 
and function that result in remodeling and persistence of the arrhythmia. AF can cause 
loss of contractility and increased compliance that result in atrial dilation.
135
 Atrial stretch 
and fibrosis also can cause pathologic changes.
28
  
 The two main pathophysiologic mechanisms thought to underlie AF are a focal 
mechanism and multiple reentrant wavelets (Figure 5.1).
28
 With a focal initiation of AF, 
one or more rapidly depolarizing atrial impulses, most commonly originating in the 
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pulmonary veins, is the trigger. This mechanism is supported by a study that 
demonstrated that identification and ablation of a focal source of AF terminated the 
arrhythmia.
136
 Histologically, AF patients have atrial tissue on the pulmonary veins with 
shorter refractory periods compared to control patients.
137
 It is also possible for AF to 
begin as a result of rapid depolarization from the pulmonary veins and the subsequent 
electrical remodeling to promote multiple reentry wavelets.
138
 With multiple reentry 
wavelets, one or more circuits is involved and fractionation of wavefronts through the 
atria results in self-perpetuating “daughter wavelets.”28 The refractory period, mass and 
conduction velocity in various parts of the atria determine the number of wavelets at a 
given time.
28,139
 An increased number of wavelets, caused by a large atrial mass, short 
refractory period and delayed conduction, fosters sustained AF.
28
 Electrophysiologic 
mapping in humans supports this theory.
140
 These mechanisms are not mutually exclusive 
and can and do coexist within a patient.
28,131
   
 
Figure 5.1: Posterior view of principal electrophysiological mechanisms of atrial 
fibrillation. From Fuster V, et al. Circulation. 2006;114(7):e257-354. 
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5.2 CLASSIFICATION 
 The American College of Cardiology, American Heart Association and European 
Society of Cardiology recommend the following consensus classification scheme 
developed with an emphasis on simplicity and clinical relevance.
28
 AF can be classified 
as either the first-detected episode or recurrent (Figure 5.2). If a patient has two or more 
episodes of AF, it is classified as recurrent and can be further subclassified based on 
duration and response to treatment; both paroxysmal and persistent AF can be recurrent.
28
 
An AF episode that spontaneously terminates within seven days is classified as 
paroxysmal. AF is classified as persistent if an episode lasts more than seven days, 
regardless of if the episode self-terminates or requires pharmacological therapy or direct 
current cardioversion.
28
 Longstanding AF (greater than one year) in which cardioversion 
was not successful or not attempted is classified as permanent.
28
 These categories are not 
mutually exclusive within a patient. For example, a patient might have episodes of 
paroxysmal and persistent AF.
28
 
 
Figure 5.2: Patterns of atrial fibrillation. From Gillis AM, et al. Can J Cardiol. 
2011;27(1):47-59. 
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In addition to the above classifications, AF in individuals under 60 years of age 
without evidence of cardiopulmonary disease, including hypertension or diabetes, is 
classified as lone AF.
28,141
 Nonvalvular AF is defined as AF in individuals without 
rheumatic mitral valve disease, a prosthetic heart valve or mitral valve repair.
28
  
 
5.3 RECURRENCE AND PROGRESSION 
 Among patients with first detected AF, approximately 54% experienced a 
recurrent event within one year of diagnosis.
142
 During one year of follow-up, one-third 
of general practice patients in France with a diagnosis of paroxysmal AF had 
recurrence.
143
 By five years, 63.2% of patients with paroxysmal AF experienced 
recurrence.
144
 Recurrence is likely underestimated as many episodes go undiagnosed, in 
part because they often are asymptomatic.  
 In addition to being recurrent, AF is a progressive disease. The rate of progression 
from paroxysmal to a more advanced disease state (either persistent or permanent) is 
highest in the first year after diagnosis.
144,145
 Among patients with paroxysmal AF, 8.6% 
progressed to permanent AF within the first year and 24.7% progressed to permanent AF 
within five-years.
144
 A similar probability of progression to permanent AF was found 
when paroxysmal and persistent AF were combined.
146
 The progression rate from 
paroxysmal to persistent or permanent AF was 13.6 per 100 person-years during the first 
year of follow-up and 6.2 per 100 person-years during a mean follow-up of 2.7 years.
145
 
 In multivariable analysis independent predictors of progression of AF from 
paroxysmal to persistent or permanent included history of HF, hypertension, chronic 
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obstructive pulmonary disease, history of stroke or transient ischemia attack and age > 75 
years.
147
 Diagnosis of cardiomyopathy, aortic stenosis, mitral regurgitation and left atrial 
enlargement also have been found to be independent predictors of progression in 
multivariable analysis.
144
 
 
5.4 ATRIAL FIBRILLATION VERSUS ATRIAL FLUTTER 
 AF and atrial flutter (AFL) are both tachyarrhythmias, but historically have been 
viewed as two separate conditions with distinct International Classification of Diseases, 
ninth revision, (ICD-9) codes of 427.31 for AF and 427.32 for AFL.
28,131
  
During AF the atrial rate ranges from 350 to 600 beats per minute (BPM).
28,131
 As 
a consequence of concealed atrioventricular (AV) nodal penetration and subsequent AV 
block of varying degrees, the classic characteristic of irregularly irregular ventricular rate 
ranges between 100 to 160 bpm.
131
 On ECG, the absence of distinct P-waves before each 
QRS complex, rapid atrial oscillations (F waves) and variable RR intervals indicate AF 
(Figure 5.3).
28,131
  
 
Figure 5.3: Rhythm strip of AF. From Goodacre S, Irons R. BMJ. 2002;324(7337):594-
597.  
 AFL is defined by a single reentrant circuit confined to the right atrium.
131
 AFL is 
characterized by an atrial rate between 250 and 350 bpm, a regular ventricular rhythm 
and a 2:1 AV conduction which results in a ventricular rate of about 150 bpm.
131
 On 
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ECG, regular, broad, saw-toothed F-waves (flutter waves) are seen, especially in the 
inferior leads (Figure 5.4).
28,131
 
 
 
Figure 5.4: Rhythm strip of AFL. From Goodacre S, Irons R. BMJ. 2002;324(7337):594-
597.   
 It is increasingly documented that AF and AFL can occur in isolation or in 
combination. AFL can precede or coexist with AF and AFL frequently degenerates into 
AF.
28
 In addition, the increased risk of thromboembolism is present in both AF and AFL, 
which has resulted in identical antithrombotic clinical performance measures.
148
 Also, the 
tenth revision of the ICD codes (ICD-10) combines AF and AFL into one code, I48.   
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6.0 CLINICAL ASPECTS 
 
6.1 DIAGNOSIS 
 AF is often asymptomatic and consequently undiagnosed.
149
 Individuals with AF 
may have no, episodic or severe symptoms.
149
  When symptoms are present they include 
palpitations, fatigue, lightheadedness and dyspnea on exertion.
149
  
 Given that AF often occurs without symptoms, it frequently is diagnosed during a 
routine ECG examination, based on data from an implanted pacemaker, during 
ambulatory ECG monitoring or during the course of treatment for MI or stroke.
149
 In the 
CHS, 12% of AF cases were diagnosed incidentally during annual study ECGs.
8
 On 
ECG, AF is characterized by the absence of distinct P-waves prior to each QRS complex, 
the presence of rapid atrial oscillations (F-waves) varying in amplitude, shape and timing 
and irregular RR intervals.
131
  
 The initial evaluation of a patient with suspected or proved AF focuses on 
characterizing the arrhythmia as paroxysmal or persistent, pinpointing its cause and 
identifying associated cardiac and extracardiac factors relevant to the etiology, 
tolerability and management.
28
 A diagnosis of AF requires supporting ECG 
documentation with a minimum of a single-lead recording during the arrhythmia. 
Additionally, all patients with AF should have 2-dimensional Doppler echocardiography 
to assess left atrium and left ventricle dimensions and left ventricle wall thickness and 
function.
28
 A thorough history and diagnostic workup (Table 6.1) are used to guide 
therapy and usually can occur during a single outpatient appointment.
28
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Minimum evaluation 
1. History and physical examination, to define 
 Presence and nature of symptoms associated with AF 
 Clinical type of AF (first episode, paroxysmal, persistent, or permanent) 
 Onset of the first symptomatic attack or date of discovery of AF 
 Frequency, duration, precipitating factors, and modes of termination of AF 
 Response to any pharmacological agents that have been administered 
 Presence of any underlying heart disease or other reversible conditions 
(e.g., hyperthyroidism or alcohol consumption) 
2. Electrocardiogram, to identify 
 Rhythm (verify AF) 
 LV hypertrophy 
 P-wave duration and morphology of fibrillatory waves 
 Preexcitation 
 Bundle-branch block 
 Prior MI 
 Other atrial arrhythmias 
 To measure and follow the R-R, QRS, and QT intervals in conjunction 
with antiarrhythmic drug therapy 
3. Transthoracic echocardiogram, to identify 
 Valvular heart disease 
 LA and RA size 
 LV size and function 
 Peak RV pressure (pulmonary hypertension) 
 LV hypertrophy 
 LA thrombus (low sensitivity) 
 Pericardial disease 
4. Blood tests of thyroid, renal, and hepatic function 
 For a first episode of AF, when the venticular rate is difficult to control 
 
Additional testing (One or several tests may be necessary) 
1. Six-minute walk test 
 If the adequacy of rate control is in question 
2. Exercise testing 
 If the adequacy of rate control is in question (permanent AF) 
 To reproduce exercise-induced AF 
 To exclude ischemia before treatment of selected patients with a type Ic 
antiarrhythmic drug 
3. Holter monitoring or event recording 
 If diagnosis of the type of arrhythmia is in question 
 As a means of evaluating rate control 
4. Transesophageal echocardiography 
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 To identify LA thrombus (in the LA appendage) 
 To guide cardioversion 
5. Electrophysiological study 
 To clarify the mechanism of wide-QRS-complex tachycardia 
 To identify a predisposing arrhythmia such as atrial flutter or paroxysmal 
supraventricular tachycardia 
 To seek sites for curative ablation or AV conduction block/modification 
6. Chest radiograph, to evaulate 
 Lung parenchyma, when clinical findings suggest an abnormality 
 Pulmonary vasculature, when clinical findings suggest an abnormality 
 
 
 
Table 6.1: Clinical evaluation in patients with AF. Type IC refers to the Vaughan 
Williams classification of antiarrhythmic drugs; AV indicates atrioventricular; LA, left 
atrial; LV, left ventricular; MI, myocardial infarction; RA, right atrial; RV, right 
ventricular. Reproduced from Fuster V, et al. Circulation. 2006;114(7):e257-354. 
 
6.2 TREATMENT 
 The primary treatment objectives of AF patients are correction of rhythm 
disturbance, heart rate control and prevention of thromboembolism (Figure 6.1). The 
initial treatment decision is focused on selecting a rhythm control or rate control 
strategy.
28
 The rhythm-control strategy focuses on reestablishing and maintaining sinus 
rhythm and the rate-control strategy focuses on controlling the ventricular rate. 
Regardless of the strategy selected, antithrombotic therapy is necessary for the prevention 
of thromboembolism.
28
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Figure 6.1: Overview of atrial fibrillation management. From Gillis AM, et al. Can J 
Cardiol. 2011;27(1):47-59. 
Rhythm control treatment options include pharmacological therapy, electrical 
cardioversion, catheter ablation, the maze procedure, atrial pacing and implantation of an 
internal atrial defibrillator. The potential benefits of a rhythm control strategy include 
fewer symptoms, increased exercise capacity, improved hemodynamic function and 
prevention of tachycardia-induced cardiomyopathy as a result of AF.
28
 However, 
antiarrhythmic medication often is unsuccessful in maintaining sinus rhythm and can 
have serious adverse effects.
28
 Pharmacological therapy is the first line of treatment with 
a rhythm control strategy. The primary medications used for pharmacologic 
cardioversion are class Ia, Ic and III antiarrhythmics.
150
 Flecainide and propafenone, class 
Ic agents, are commonly used and have similar efficacy.
150
 Class Ic drugs have the 
highest efficacy for recent-onset AF while class III drugs are best for persistent AF.
150
 
Electrical cardioversion involves ECG monitoring and delivery of an electrical shock 
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synchronized with the intrinsic activity of the heart; the ECG monitors the R wave to 
prevent stimulation during the vulnerable phase of the cardiac cycle.
28
 Cardioversion can 
be performed with or without the use of antiarrhythmic drugs.
28
 Electrical cardioversion 
is successful in 70% to 90% of patients; short duration of AF, presence of AFL and 
younger age are predictors of successful cardioversion.
150
 In patients with a structurally 
normal heart, catheter-based radiofrequency ablation, pulmonary vein isolation or linear 
ablation to compartmentalize the atrium can be used to target the arrhythmogenic foci in 
the pulmonary veins, the atria, superior vena cava or the coronary sinus.
150
 These 
procedures have a success rate up to 80% in patients with a single focus of AF who had 
limited ablation or in healthy patients who underwent complete pulmonary vein isolation 
for paroxysmal or persistent AF.
151
 The procedural success decreases to 50-60% in 
patients with permanent AF and significant structural heart disease.
151
 Recurrent AF 
following successful ablation occurs in up to 40% of patients.
151,152
 The maze procedure, 
indicated for highly symptomatic, drug-resistant AF patients or patients who experience 
thromboembolism while on warfarin, is effective in more than 90% of cases.
150
 While 
highly effective, the procedure is not widely utilized, in part because it requires the use of 
cardiopulmonary bypass.
28
 In the maze procedure surgical scars are created in the left 
atrium and the pulmonary veins are isolated.
150
 By creating conduction barriers in the 
atrium, this procedure prevents the propagation of reentry wavefronts.
150
 Atrial pacing, 
either in the right atria or in multiple locations, works by altering the pattern of atrial 
depolarization and suppression of premature atrial beats.
28,150
 However, the usefulness of 
this approach has yet to be proved.
28,150
 Patients with recurrent, drug-resistant, highly 
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symptomatic AF are potential candidates for implantation of an internal atrial 
defibrillator.
150
 Delivery of a synchronous shock between the high right atrium and 
coronary sinus is known to effectively terminate an episode of AF.
153
 Implantable cardiac 
defibrillator (ICD) technology has made great progress and now ICD devices can detect, 
treat and prevent AF.
150
 Despite the efficacy of ICDs, patients find the shock 
uncomfortable and therefore this device has limited clinical use.
28,150
 
Rate control treatment modalities include pharmacological therapy, ablation and 
pacemaker implantation. Benefits of a rate control strategy include a simplified treatment 
plan and use of less toxic medication, with fewer side effects, than antiarrhythmic 
medication.
28
 Current guidelines for rate control are a ventricular rate of 60-80 BPM at 
rest and 90-115 BPM during moderate exercise.
28
 The main determinants of ventricular 
rate are the intrinsic conduction characteristics, refractoriness of the AV node and 
sympathetic and parasympathetic tone.
28
 Pharmacological therapy is the primary 
treatment choice and medications that prolong the refractory period are generally 
effective for rate control because of the inverse correlation between the functional 
refractory period of the AV node and the ventricular rate.
28
  Beta blockers, calcium 
channel antagonists and digitalis are used individually or in combination to achieve rate 
control.
28
 If pharmacological therapy is unsuccessful, AV nodal ablation and permanent 
pacemaker implantation is an effective method to control the heart rate and improve 
symptoms.
131,154
  
 Consensus has not been reached on the preferred treatment strategy, rhythm or 
rate control, for AF patients. Historically, rhythm control was considered the best 
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treatment approach.
155
 However, since the publication of the Atrial Fibrillation Follow-
Up Investigation of Rhythm Management (AFFIRM) trial results in 2002, either strategy 
has been considered acceptable.
28,152
 In the AFFIRM trial there was no difference in the 
primary endpoint of all-cause mortality between rhythm and rate control strategies (HR: 
1.15; 95% CI: 0.99 – 1.34; p = 0.08); rates of the composite end point of death, disabling 
stroke, disabling anoxic encephalopathy, major bleeding, or cardiac arrest were also 
similar between the two groups.
155
 More patients in the rhythm control group were 
hospitalized during following-up.
155
 Similar results were reported from four smaller 
randomized controlled trials, published around the same time as AFFIRM; in each of the 
studies there was no difference in all-cause mortality between rate and rhythm control.
156-
159
 A meta-analysis of these five trials reported a pooled OR for all-cause mortality 
comparing rate and rhythm control groups of 0.87 (95% CI: 0.74 – 1.02; p = 0.09).160 
Additionally, there was no difference in the odds of ischemic stroke between the rate and 
rhythm control groups in any of the three individual trials
155-157
 or in the pooled estimate 
(OR: 0.50; 95% CI: 0.14 – 1.83; p = 0.30).160 Despite evidence that the rate and rhythm 
treatment strategies result in similar patient outcomes, the generalizability of the trial 
results to the general AF patient population has been questioned. A recent population-
based study with a mean follow-up duration of 3.1 years (standard deviation 2.3 years) 
found the effect of rate versus rhythm control drugs changed over time; in the first six 
months, mortality was slight higher among patients treated with rhythm control drugs, 
mortality was similar between groups until year four and then mortality among those 
treated with rhythm control decreased (5-year HR: 0.89; 95% CI: 0.81 – 0.96; 8-year HR: 
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0.77; 95% CI: 0.62 – 0.95).161 In analyses that accounted for treatment crossovers, the 
long-term mortality reduction was even greater for patients who initiated and maintained 
rhythm control therapy compared to those who initiated and maintained rate control 
therapy.
161
   
 Regardless of the treatment strategy, antithrombotic therapy currently is 
recommended for AF patients, except those with lone AF or contraindications, to prevent 
thromboembolism (Table 6.2).
28
 Several stroke risk classification schemes have been 
developed in order to stratify the risk of ischemic stroke in AF patients. The CHADS2 
classification scheme (congestive HF, hypertension, age, diabetes, stroke [doubled]) 
incorporates elements from the Atrial Fibrillation Investigators (AFI) and Stroke 
Prevention and Atrial Fibrillation (SPAF) schemes to quantify stroke risk and select the 
appropriate antithrombotic therapy.
162
 The American Heart Association and the American 
Stroke Association recently published a science advisory on the use of oral 
antithrombotic agents for the prevention of stroke; warfarin, dabigatran, apixaban and 
rivaroxaban are all recommended for the prevention of first and recurrent stroke in 
patients with nonvalvular AF.
163
 Antithrombotic therapy is recommended for patients at 
high stroke risk
163
 and aspirin for patients at low stroke risk.
164,165
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Table 6.2: Antithrombotic therapy for patients with atrial fibrillation. From Fuster V, et 
al. Circulation. 2006;114(7):e257-354. 
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7.0 CONCOMITANT CLINICAL EVENTS 
 
7.1 ACUTE MYOCARDIAL INFARCTION 
AF frequently complicates acute MI. The incidence of AF among MI patients 
varies between 6% and 22%.
166
 In Olmsted County residents who experienced a first MI, 
10% had AF prior to MI and 23% developed AF after the event.
22
 A recent systematic 
review and meta-analysis reported that among MI patients roughly one in 10 had 
concomitant AF.
23
 Both conditions dramatically increase in frequency with advancing 
age. Among elderly Medicare beneficiaries, MI patients who presented with AF were 
older, had a higher heart rate, had more advanced HF and were more like to have a 
history of coronary artery bypass graft surgery, previous MI and cerebrovascular disease 
compared to MI patients who developed AF during MI hospitalization.
167
 The biological 
mechanisms involved in the development of AF during MI have not been fully 
elucidated. Potential mechanisms include pericarditis, atrial ischemia or infarction, 
increased catecholamines, metabolic abnormalities and increased atrial pressures.
167
 
Patient prognosis is worse for those who experience both MI and AF compared to those 
who have either condition individually.
22,23,167,168
 
 
7.2 HEART FAILURE 
AF and HF frequently coexist, partly because of shared risk factors and partly 
because they predispose to each other. Age, hypertension, MI, diabetes, obesity and 
valvular heart disease are risk factors for both AF and HF.
169
 AF may influence the 
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development and progression of HF in a number of ways (Figure 7.1). During AF, an 
increase in resting heart rate as well as an exaggerated heart rate response to exercise 
shorten the diastolic filling time which in turn results in lower cardiac output. In addition, 
irregular ventricular contraction reduces overall cardiac output because the reduction in 
left ventricular filling during short cycles is not fully compensated for by the increased 
filling during longer cycles. Reduced contractile function of the atrium also plays an 
important role in the reduction of cardiac output.
169
 Likewise, HF increases the risk of AF 
in multiple ways, including elevation of cardiac filling pressures, deregulation of 
intracellular calcium and autonomic and neuroendocrine dysfunction.
169
  
 
Figure 7.1: Atrial fibrillation and heart failure: a vicious pathophysiological cycle. 
Reproduced from Anter E, Jessup M, Callans DJ. Circulation. 2009;119(18):2516-2525. 
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In the FHS, 1470 participants developed incident AF or HF between 1948 and 
1995; a quarter (n = 382) developed both AF and HF.
21
 AF preceded HF approximately 
as often as HF preceded AF, 38% and 41%, respectively, and 21% had both diagnosed on 
the same day.
21
 The unadjusted incidence of HF following incident AF was slightly 
higher in Olmsted County at 44 per 1,000 person-years,
20
 compared to the FHS at 33 per 
1,000 person-years.
21
 
 
7.3 STROKE 
 AF was associated with a five-fold increased risk of ischemic stroke in the FHS.
19
 
Among Olmsted County residents diagnosed with incident AF, 11% had a first ischemic 
stroke over a mean follow-up of 5.5 years.
18
 A collaborative analysis of five randomized 
controlled trials identified advanced age, history of hypertension, previous transient 
ischemic attack or stroke and diabetes as independent risk factors for stroke among AF 
patients.
170
 The relative risk of stroke associated with AF was fairly stable across age 
groups; however, the attributable risk increased significantly with age, from 1.5% to 
23.5% among 50-59 and 80-89 year olds, respectively.
19
 Ischemic stroke and systemic 
arterial occlusion in AF are primarily attributed to embolism of a thrombus as a result of 
blood stasis in the left atrium.
28
 Nevertheless, up to 25% of strokes in AF patients might 
be a result of intrinsic cerebrovascular diseases, other cardiac sources of embolism or 
atherosclerotic pathology in the proximal aorta.
171,172
 Treatment with warfarin reduced 
the risk of stroke by 68% (95% CI: 50% 79%).
170
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7.4 COGNITIVE IMPAIRMENT 
 There is increasing evidence that AF is a risk factor for cognitive impairment. 
Several cross-sectional studies found that after adjustment for cardiovascular risk factors, 
AF was associated with cognitive dysfunction, independent of stroke.
173-175
 In the cross-
sectional portion of the Rotterdam Study, participants with AF had an adjusted 2-fold 
increased prevalence of dementia.
175
 A prospective cohort study among residents of 
Olmsted County with incident AF and without stroke found the cumulative rate of 
dementia was 2.7% and 10.5% at one and five years, respectively.
25
 A meta-analysis 
restricted to studies conducted among non-stroke AF patients reported a pooled OR of 
dementia of 1.64 (95% CI: 1.00 – 2.71; p = 0.05) comparing those with and without AF.24 
 
7.5 DEATH 
 AF is associated with an increased risk of death. Among newly diagnosed AF 
patients, the risk of death is extremely high; within the first four months of diagnosis, the 
HR for death among those with AF compared to those without AF was 9.62 (95% CI: 
8.93 – 10.32).45 The risk of death for the remainder of the 21-year follow-up was 1.66 
(95% CI: 1.59 – 1.73).45 The most common causes of cardiovascular death were coronary 
artery disease, HF and ischemic stroke, accounting for 22%, 14% and 10%, respectively, 
of deaths within 4 months of AF diagnosis and 15%, 16% and 7%, respectively of later 
deaths.
45
 In the FHS, the adjusted odds of death in men with AF were 1.5-fold greater 
(95% CI: 1.2 – 1.8; p = 0.0001) compared to men without AF; among women the odds of 
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death were 1.9-fold greater (95% CI: 1.6 – 2.3; p = 0.0001) in those with AF.26 The death 
rate per 1,000 person-years among initially healthy women with and without new-onset 
AF was 10.8 (95% CI: 8.1 – 13.5) and 3.1 (95% CI: 2.9 – 3.2), respectively.46 Among 
elderly Medicare beneficiaries, mortality following AF diagnosis declined slightly over 
time but remained high.
27
 In 2007, the age- and sex-adjusted mortality at 30 days and 1-
year were 10.8% and 24.7%, respectively.
27
 Mortality following an inpatient diagnosis of 
AF was significantly higher than mortality following an outpatient diagnosis; in 2007 the 
one-year mortality following an inpatient diagnosis was 32.3% compared to 10.2% 
following an outpatient diagnosis.
27
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8.0 ATHEROSCLEROSIS RISK IN COMMUNITIES STUDY 
 
8.1 OVERVIEW 
The ARIC study is a prospective epidemiologic study of CVD conducted in four 
US communities: Forsyth County, NC; the city of Jackson, MS; eight northwestern 
suburbs of Minneapolis, MN; and Washington County, MD. The ARIC study has both 
cohort and community surveillance components and was designed to investigate the 
etiology and natural history of atherosclerosis, the etiology of clinical atherosclerotic 
disease and differences in cardiovascular risk factors, medical care and disease by race, 
sex, location and date.
176,177
  
 
8.2 ATHEROSCLEROSIS RISK IN COMMUNITIES SURVEILLANCE 
COMPONENT 
 
8.2.1 STUDY OBJECTIVES 
The community surveillance component of ARIC was designed to provide 
knowledge about the burden of and trends in CHD morbidity and mortality in four US 
communities. The specific objectives of the community surveillance component are to 
estimate CHD incidence, case fatality and mortality using standardized criteria and 
methods and to elucidate the availability and use of medical care in four US 
communities.
177
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8.2.2 STUDY DESIGN AND POPULATION 
Continuous retrospective surveillance of hospitalized acute MI and in- or out-of 
hospital death due to CHD was initiated in 1987 in the four ARIC communities. 
Hospitalized MI and deaths due to CHD in residents of the ARIC communities age 35 – 
74 years were eligible for inclusion;
177
 beginning in 2005 residents aged 75 – 84 years 
were eligible. Community boundaries were defined by county lines in Forsyth County, 
NC, and Washington County, MD, and by metropolitan boundaries in Jackson, MS, and 
the suburbs of Minneapolis, MN.
177
 In order to calculate rates, age, sex and race-specific 
population estimates were calculated from U.S. censuses; in 1987 the total population of 
each community was as follows: Forsyth County, NC, 108,815 (22,236 black), Jackson, 
MS, 71,000 (30,398 black), suburbs of Minneapolis, MN, 85,134 and Washington 
County, MD, 50,631.
177
  
 
8.2.3 DATA COLLECTION 
 Fatal CHD events in Forsyth County, NC, Jackson, MS, and the suburbs of 
Minneapolis, MN, were identified monthly from state vital statistics files containing a list 
of deaths and the corresponding death certificates that met age, residence and cause of 
death eligibility criteria. State nosologists used the rules of the ICD-9 to code the cause of 
death and the underlying cause of death was assigned by the Automated Classification of 
Medical Entities (ACME).  In Washington County, MD, death certificates were obtained 
directly from the county health department and the ACME underlying case of death was 
determined in conjunction with the National Center for Health Statistics. A systematic 
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sampling fraction was used to reduce the number of abstracted death certificates that did 
not lead to a valid CHD death. Deaths that occurred out of the state of residence or within 
the state of residence but at a hospital not part of the community catchment area were not 
captured. Death certificates were reviewed by trained abstractors and classified into one 
of five categories.
177
  
 Hospitalized MIs were ascertained through annual lists of selected discharge 
diagnosis codes from hospitals located within the ARIC community and those outside the 
community where six or more community residents had deaths coded as ICD-9 410 – 414 
in 1984 – 1985. The hospital list of discharge diagnosis codes also included information 
on age, date of birth, address, zip code, vital status at discharge and date of discharge that 
were used to determine study eligibility. All hospitalizations that met eligibility criteria 
and had an ICD-9 discharge diagnosis for MI (410.x) were abstracted. A sample of 
discharge codes potentially related to CHD was abstracted. Sampling probabilities were 
adjusted periodically and differed by sex, race, field center and discharge code 
group.
178,179
 Trained and certified abstractors reviewed hospital records for cases meeting 
age, residence and discharge diagnosis code eligibility and recorded clinical data onto 
standardized collection forms. Data included presenting symptoms, including chest pain, 
history of CVD, timing and onset of symptoms, medications on admission, during 
hospitalization or at discharge, diagnostic and therapeutic procedures, cardiac enzyme 
levels and ECGs. A computerized diagnostic algorithm was applied to each 
hospitalization and classified the event into one of four categories: definite, probable, 
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suspect or no MI.
177
 Additionally, the ARIC Mortality and Morbidity Classification 
Committee adjudicated MI diagnoses.
177
 
 
8.2.4 ATRIAL FIBRILLATION ASCERTAINMENT 
 Presence of AF during the MI hospitalization was identified by the presence of 
AF ICD-9 hospital discharge diagnosis codes of 427.3x in any position. The ARIC 
Mortality and Morbidity Classification Committee did not adjudicate AF diagnosis. 
Validity of ICD codes for the identification of AF has been described elsewhere.
180
  
 
8.3 ATHEROSCLEROSIS RISK IN COMMUNITIES COHORT 
COMPONENT 
 
8.3.1 STUDY OBJECTIVES 
The cohort component of the ARIC Study was designed to identify characteristics 
associated with the development and progression of clinical atherosclerosis as measured 
by carotid B-mode ultrasonography, to identify risk factors associated with incident 
atherosclerotic events and to measure variation in risk factors over time.
177
  
 
8.3.2 STUDY DESIGN AND POPULATION 
The ARIC Study recruited a prospective cohort of white and black adults between 
45 and 64 years of age at baseline, 1987 – 1989, from four U.S. communities: Forsyth 
County, NC, the city of Jackson, MS, eight northwest suburbs of Minneapolis, MN, and 
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Washington County, MD.
176
 Approximately 4,000 participants were selected from each 
community using community specific probability sampling; households were identified 
by area sampling in Forsyth County, NC, driver’s licenses or state identification cards 
were used in Jackson, MS, eligibility for jury duty (with driver’s license, voter 
registration cards or identification cards) were applied in Minneapolis, MN, and driver’s 
licenses or inclusion in a 1975 private county health census were utilized in Washington 
County, MD. Regardless of the community, all age-eligible residents of an identified 
household were selected as potential participants. Only blacks were recruited from the 
city of Jackson, MS; the other sites included both whites and blacks although < 5% of the 
population in Minneapolis, MN, and Washington County, MD, were black. A total of 
15,792 participants enrolled at baseline (8710 women, 4314 blacks). Participants had a 
clinical exam at baseline and were reexamined every three years, 1990-92, 1993-95 and 
1996-98. The response rates for visits 2 (1990 – 1992), 3 (1993 – 1995) and 4 (1996 – 
1998) were 93%, 86% and 81%, respectively. A fifth follow-up clinical exam started in 
May 2011 and was completed in 2013. Annual telephone calls are used to maintain 
contact with participants and identify medical events and death.
176
 Follow-up is complete 
through December 31, 2010. 
 
8.3.3 DATA COLLECTION 
Between 1987 and 1989 baseline data were collected; the baseline exam consisted 
of a home interview comprised of questionnaires about cardiovascular risk factors, 
socioeconomic status, and family medical history as well as a clinical examination. The 
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baseline clinical exam and each of the three triennial follow-up exams consisted of 
anthropometry, sitting blood pressure, venipuncture, ECG, ultrasound, physical exam and 
interviewer-administered questionnaires on medical history, health behaviors (alcohol 
and tobacco use) and social characteristics. Additional data were collected at some 
exams; for example, interview-administered questionnaires on physical activity and diet 
were conducted at baseline and exam 3 while pulmonary function was measured at 
baseline and exam 2. In addition, annual telephone calls continue to maintain contact 
with participants and to identify any cardiovascular events, hospitalizations and death. It 
is of particular important to this proposal that only the baseline ECG included a two-
minute rhythm strip. Each center’s institution review board approved the study and all 
participants provided written informed consent.
176
 
 
8.3.4 MEDICARE LINKAGE 
The ARIC study has an Interagency Agreement with the Centers for Medicare and 
Medicaid Services (CMS) to obtain Medicare data on ARIC cohort participants. The 
Collaborative Studies Coordinating Center provides ARIC participants’ social security 
number, sex, and date of birth to Medicare and by referencing this information ARIC 
participants are linked to CMS data. Of the 15,738 ARIC participants alive as of January 
1, 1991, 14,530 (92.3%) were matched successfully and linked to CMS Medicare claims.  
Matched participants are linked to the following Medicare files: the Master Beneficiary 
Summary File, Medicare Provider Analysis and Review (MedPAR), Carrier, Outpatient 
and Prescription Drug Event (PDE). The Master Beneficiary Summary File contains four 
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segments: the beneficiary summary file, chronic conditions, cost and utilization and 
National Death Index information. The MedPAR file contains claims for inpatient 
services covered under Medicare Part A. The outpatient files contain claims for services 
covered under Medicare Part B, including institutional claims (Outpatient file) for 
outpatient services and noninstitutional physician claims (Carrier file). The PDE file 
contains information on outpatient prescription drugs. CMS claims for inpatient and 
outpatient services have been available for research since 1991, while prescription drug 
information has been available since 2006 when Part D commenced.  ARIC has 
enrollment, inpatient and outpatient claims data from 1991 through 2010 and prescription 
drug information from 2006 through 2010. The annual beneficiary summary file 
identifies Medicare enrollment periods for Parts A, B, C and D for ARIC participants.  
Analyses for Manuscript 2, Part 10.0, and Manuscript 3, Part 11.0, will be 
restricted to ARIC participants who enrolled in fee-for-service (FFS) Medicare, both 
Parts A and B, because Medicare Advantage plans are not required to submit claims for 
their beneficiaries and incomplete claims data are available for those enrolled in only Part 
A.  
 
8.3.5 ATRIAL FIBRILLATION ASCERTAINMENT 
Utilizing ARIC data, prevalent AF was identified by baseline ECG. Incident AF 
was identified by ECG during follow-up study visits, hospital discharge codes and death 
certificates.
7
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Standard supine 12-lead resting ECGs were recorded at least one hour after 
consumption of caffeine or tobacco and transmitted to the ARIC ECG Reading Center for 
coding and interpretation. The baseline ECG had a two-minute rhythm strip and 
subsequent ECGs had a 10-second reading. ECGs automatically coded as AF were 
visually checked by a trained cardiologist to confirm the diagnosis.
181
 All ECGs were 
recorded using MAC PC Personal Cardiographs (Marquette Electronics, Inc., Milwaukee, 
WI).  
Hospitalizations were identified by annual telephone calls to participants and 
through surveillance of local hospital discharges in each of the ARIC communities.
176,177
 
A hospital discharge code, ICD-9 code of 427.3, 427.31 or 427.32, in any position, 
indicates AF. 
AF was identified though death certificates with an ICD-10 code I48 or ICD-9 
code 427.3x as the underlying cause of death. The AF incidence date was defined as the 
first documented occurrence of AF on ECG, hospital discharge diagnosis or death 
certificate. In ARIC, two analyses were performed to determine the validity of the 
diagnosis of incident AF based on hospital discharge diagnosis codes.
7
 First, a sample of 
125 hospital discharge summaries with a first ICD-9 code for AF and ECGs performed 
during that hospitalization were reviewed by a study physician; the positive predictive 
value (PPV) for AF was 89% and for incident AF was 62%.
7
 Second, a trained abstractor 
used information routinely collected for stroke ascertainment to complete a form with 
data from the complete medical record. The form includes information on the presence of 
AF during four weeks prior to the stroke hospitalization. Of 161 participants with AF 
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recorded in the stroke abstraction form, 135 had an ICD code for AF (sensitivity = 84%) 
and of 1385 participants without AF in the abstraction form, 34 had an ICD code for AF 
(specificity = 98%).
7
 The sensitivity of using hospital discharge codes to identify AF was 
similar in the CHS; hospital discharge diagnoses codes (ICD-9 code of 427.3x) correctly 
identified 29 (70.7%) of the 41 participants with AF or AFL on at least one ECG.
8
 A 
recent systematic review of algorithms used in administrative data to identify AF patients 
reported a median PPV of 89% (range: 70% - 96%) and a median sensitivity of 79% 
(range: 57% - 95%).
180
    
Utilizing CMS data, incident AF was defined as an AF discharge diagnosis (ICD-
9 code 427.3, 427.31 or 427.32), in any position, on a single inpatient (MedPAR) claim 
or as a diagnostic code on two outpatient claims within 7 – 365 days. A minimum of two 
outpatient claims at least 7 days apart were required to reduce the likelihood of including 
“rule out” diagnoses and to improve algorithm specificity.27,182,183 Additionally, requiring 
at least two outpatient or physician claims can be used to define the presence of chronic 
disease in Medicare claims data.
184
 The incidence date of AF was defined as the 
discharge date for a MedPAR short-stay claim or the date of the second qualifying 
outpatient claim, whichever occurred earlier. Secondary CMS definitions of AF were 
restricted to only MedPAR claims criteria and only outpatient claims criteria. 
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9.0 MANUSCRIPT 1 – TEMPORAL TRENDS IN THE OCCURRENCE AND 
OUTCOMES OF ATRIAL FIBRILLATION IN PATIENTS WITH ACUTE 
MYOCARDIAL INFARCTION: THE ATHEROSCLEROSIS RISK IN 
COMMUNITIES SURVEILLANCE STUDY 
 
9.1 OVERVIEW 
Background: AF frequently coexists in the setting of MI, being associated with 
increased mortality. Nonetheless, temporal trends in the occurrence of AF complicating 
MI and in the prognosis of these patients are not well described. We examined temporal 
trends in prevalence of AF in the setting of MI and the impact of AF on prognosis in the 
community. 
Methods and Results: We studied a population-based sample of 20,049 validated first 
incident nonfatal hospitalized MIs among 35- to 74-year old residents of four 
communities in the ARIC Study from 1987 through 2009. Prevalence of AF in the setting 
of MI increased during the 23-year study period, from 11% to 15% (multivariable 
adjusted OR for prevalent AF: 1.11 (95% CI: 1.04 – 1.19) per five-year increment). 
Overall, in patients with MI AF was associated with increased 1-year mortality (OR 1.47, 
95% CI 1.07-2.01), compared to those with no AF. However, there was no evidence that 
the impact of AF on MI survival changed over time or differed over time by sex, race or 
MI classification (all p-values > 0.10). 
Conclusions: Co-occurrence of AF in MI slightly increased between 1987 and 2009. The 
adverse impact of AF on survival in the setting of MI was consistent throughout. In the 
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setting of MI, co-occurrence of AF should be viewed as a critical clinical event, and 
treatment needs unique to this population should be explored further. 
 
9.2 INTRODUCTION 
Despite the significant decline in the incidence rate of MI since the end of the 20
th
 
century,
185-187
 the estimated annual incidence of MI in the US remains high at 525,000 
cases.
31
 AF, the most common sustained cardiac arrhythmia, often coexists with MI.
166
 A 
recent systematic review and meta-analysis reported that among MI patients 
approximately one in 10 had concomitant AF.
23
 The presence of AF was associated with 
a significantly increased risk of death among MI patients; the pooled mortality OR 
associated with AF was 1.46 (95% CI: 1.35 – 1.58).23   
Notwithstanding the frequent co-occurrence of AF with MI and the adverse 
impact on survival, little is known about the temporal trends related to the association of 
AF with prognosis of MI patients. In the Worcester Heart Attack Study, from 1990 
through 2005, the mortality rate in-hospital, at 30-days and at 1-year post-discharge, was 
significantly higher among MI patients who developed AF compared to those who did 
not, after controlling for potential confounders.
168
 In-hospital mortality among MI 
patients without AF decreased steadily from 1990 to 2005 (12.8% in 1990 to 5.9% in 
2005), but decreased only slightly among those with AF (24.6% in 1990 to 21.3% in 
2005). 
168
 Among patients hospitalized with incident MI from 1983 through 2007, in 
Olmsted County, MN, concomitant AF, regardless of its timing, was associated with an 
increased risk of death (unadjusted HR: 3.77; 95% CI: 3.37 – 4.21) .22 There was no 
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evidence of a clinically meaningful improvement in survival during the study period 
among those with coexisting AF and MI.
22,168
  
Understanding temporal trends in the occurrence and outcomes of AF in the 
setting of MI is important given the common co-occurrence of these conditions. Better 
understanding of the temporal trends could facilitate identification of a more vulnerable 
population or of unmet treatment needs. Prior studies, which examined trends in 
coexisting AF with MI, were relatively small and lacked precision in trend analyses.
22,168
 
In addition, the previous epidemiologic studies on prognosis of patients with co-occurring 
AF and MI have been conducted in predominately white communities, which is a 
limitation because the decline in incidence and mortality rates for MI have been slower 
among blacks compared to whites, especially among men,
185
 and blacks have a lower risk 
of AF compared to whites.
7
  
We sought to address the lack of precision in trend analyses and the scarce data in 
nonwhite populations utilizing a large community-based biracial study for our analyses. 
Our aims were to estimate the prevalence of AF in the setting of MI over time as well as 
by sex, race and MI classification; to describe the impact of AF on mortality; and to 
assess the temporal trends in mortality among MI patients with and without concomitant 
AF overall and among subgroups defined by sex, race and MI classification.  
 
9.3 METHODS 
Study population / data source 
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The community surveillance component of the ARIC Study, described previously, 
was designed to provide knowledge about the burden of and trends in CHD morbidity 
and mortality in four US communities.
176,177
 Briefly, since 1987, the ARIC Study has 
conducted continuous surveillance of hospitalized nonfatal MIs and in- and out-of-
hospital deaths due to CHD among residents aged 35 – 74 in the four ARIC communities: 
Forsyth County, North Carolina; Jackson, Mississippi; northwest suburbs of Minneapolis, 
Minnesota; and Washington County, Maryland.  
 Hospitalized MIs were ascertained through annual electronic discharge lists from 
all hospitals serving the ARIC Study communities. Trained abstractors reviewed hospital 
records randomly sampled from annual discharge lists from each hospital on the basis of 
age, residence, and ICD-9 discharge diagnosis codes, including 402, 410 – 414, 427, 428 
and 518.4, for possible events. Sampling probabilities differed by sex, race, field center 
and discharge code group and periodically were adjusted.
178,179
 Hospitalizations for 
community residents that occurred outside the study catchment area were not included 
unless the patients were transferred to and discharged from a hospital within the 
surveillance area. The following clinical information is abstracted from hospital records 
onto standardized forms: demographic characteristics; presenting symptoms, including 
presence of chest pain; timing of symptom onset; history of MI or other cardiovascular-
related conditions; medications during hospitalization or at discharge; cardiac biomarkers 
(total creatinine phosphokinase [CK], CKMB, lactate dehydrogenase, and troponin); 
diagnostic and therapeutic procedures; and up to three copies of 12-lead ECGs were sent 
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to the Electrocardiographic Reading Center  at the University of Minnesota for 
classification according to the Minnesota code.
188
  
MI Classification  
 A standardized computerized diagnostic algorithm, based on cardiac pain, ECG 
characteristics, and cardiac biomarkers, was applied to each sampled hospitalization and 
provided the computer diagnosis as definite, probable, suspect, or no MI.
177
 Criteria for 
each of the three algorithm elements remained constant throughout the study period, 
details of which have been described.
178
 Physicians on the ARIC Mortality and Morbidity 
Classification Committee reviewed events with discordant classification between the 
computerized diagnosis and discharge diagnosis codes and determined the final 
classification.
177
 Events with abnormal or equivocal biomarker levels were further 
classified, based on Minnesota-coded ECGs
188
 and chest pain as ST-Elevation MI 
(STEMI) or non-ST-Elevation MI (NSTEMI). MI was defined as a first incident event if 
the patient’s medical record either specified no history of MI or did not include a history 
of MI. Hospitalizations occurring within 28 days were combined and considered one 
event.   
Definition of atrial fibrillation 
 Presence of AF during the MI hospitalization was defined by the presence of AF 
ICD-9 hospital discharge diagnosis codes of 427.3x in any position. Validity of ICD 
codes for the identification of AF has been described elsewhere.
180
  We did not 
distinguish between AF that started before vs. after MI. 
All-cause mortality 
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 All-cause mortality, at 28-days and one-year, was determined by medical record 
review, state death records linkage, and linkage with the National Death Index. Deaths 
were classified based on the duration from date of hospital admission until date of death.   
Assessment of covariates 
 Patient characteristics, including age, sex, and race, were abstracted from medical 
records by trained and certified study staff as were data on cardiovascular-related 
comorbidities, including a history of hypertension, stroke and diabetes. Prescription 
medications at admission, during hospitalization or at discharge and procedures were 
classified as yes or no. New therapies have been introduced during the study period and 
the impact of these therapies was estimated beginning in the year for which complete 
treatment information was available: ACE or angiotensin II inhibitors, 1992; Antiplatelet 
agents other than aspirin, 1997; and lipid-lowering agents, 1999. 
Adjustment for disease severity and clinical comorbidities was performed with a 
modified Predicting Risk of Death in Cardiac Disease Tool (PREDICT) score.
189
 The 
PREDICT score, developed in a community-based study, utilizes information routinely 
collected during a hospitalization with MI, including cardiogenic shock, clinical history 
(cardiac events and procedures), age, severity of ECG changes, congestive HF, kidney 
function, and the Charlson Comorbidity Index, to determine mortality risk. Data on renal 
function has not always been collected in ARIC community surveillance, so a modified 
PREDICT score, ranging from 0 to 21, was used;
190
 the modified score has been 
validated.
191
 
Study sample 
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 Hospitalized non-fatal first incident definite and probable MIs were eligible for 
inclusion. Patients whose race was not white or black as well as nonwhites from the 
Minneapolis and Washington County field centers were excluded (n = 442) due to 
insufficient sample size. Patients with unknown mortality status at 28-days or one-year (n 
= 342) or with incomplete covariate data (n = 91) were also excluded.  
Statistical analysis 
 The temporal trend in prevalence of coexisting AF among MI patients was 
assessed with a logistic regression model using year (continuous) as the main 
independent variable adjusted for age (5-year groups), sex, a composite race and field 
center variable, number of ICD-9 diagnosis codes, MI classification  
(STEMI/NSTEMI/Unclassified) and severity (PREDICT). The impact of AF on survival 
overall and within subgroups defined by sex, race, and MI classification were assessed 
with logistic regression models adjusted for age, sex, race, field center, MI classification, 
number of ICD-9 codes, severity (PREDICT), presentation characteristics (first systolic 
blood pressure and first pulse), medications, and therapeutic procedures. Trends in the 
association of AF with one-year mortality among MI patients were examined with 
multivariable logistic regression models. Pre-specified 2-way multiplicative interactions 
of trends in prevalence and mortality with sex, race, and MI classification were 
examined. A p<0.10 was considered evidence of effect modification.  
All analyses were weighted by the inverse of the sampling fraction and standard 
errors were computed with stratified random sample methodology to account for the 
complex sampling scheme, which was adjusted periodically to improve efficiency.
178,179
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All statistical analyses were performed using survey procedures in SAS (version 9.2; 
SAS Institute, Inc, Cary, NC). 
 
9.4 RESULTS 
Our final analytic sample included 13,155 definite and probable first incident 
MIs, for a weighted sample of 20,049. Baseline patient characteristics over time, in four-
year intervals, are shown in Table 9.1. The age and sex distributions of the sample were 
stable over the study period, with an overall mean age of 59 years at the time of 
hospitalization; women accounted for 36 percent of the sample. The prevalence of AF 
accompanying MI increased slightly over the 23-year study period, from 11 percent 
during 1987—1990 to 15 percent during 2007—2009. The proportion of MIs classified 
as NSTEMI increased during the study period. The percent of patients receiving aspirin, 
β blockers, ACE or angiotensin II inhibitors, lipid-lowering medications, antiplatelet 
agents other than aspirin, or percutaneous coronary interventions, increased during the 
study period (Table 9.2).  
The prevalence of coexisting AF in the setting of MI increased over the study 
period; the OR for concomitant AF and MI compared to MI without AF was 1.11 (95% 
CI: 1.04 – 1.19) per five-year increment, after adjustment for age group, sex, race, field 
center, MI classification, severity of MI and number of ICD-9 diagnosis codes. After 
adjustment there was no evidence that the time trend in prevalence of co-occurring AF 
and MI differed by sex (p for interaction = 0.43) or race (p for interaction = 0.69); 
however, there was evidence of a different AF time trend by MI classification (p for 
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interaction = 0.005) (Figure 9.1). The prevalence of AF in patients with NSTEMI or 
unclassified MI increased during the study period, while among STEMI patients the 
prevalence of AF decreased.  
Overall, the presence (versus absence) of AF complicating MI was associated 
with more than a 2-fold increased odds of post-MI death at 28-days and one-year, after 
adjustment for age group, sex, race, field center and year (Table 9.3). After further 
adjustment for MI classification, number of ICD-9 diagnosis codes, presentation 
characteristics, medications and therapeutic procedures, the association between AF and 
28-day mortality was attenuated, but the odds of one-year mortality were 1.47 times 
greater (95% CI: 1.07 – 2.01) among MI patients with AF compared to those without. 
This association did not differ by sex, race or MI classification.  
Among those with AF and MI, there was no evidence of improved one-year 
survival over time: after adjustment for age, sex, race by field center, MI classification, 
number of ICD-9 codes, presentation characteristics, medications and therapeutic 
procedures, the OR for one-year mortality was 0.86 (95% CI: 0.60 – 1.21) per 5-year 
increment (Table 9.4). Conversely, among those without AF, the adjusted OR for one-
year mortality was 0.74 (95% CI: 0.62 – 0.88) per 5-year increment of time. There was 
no statistical evidence that the trend in one-year MI survival differed for those with 
versus without AF (p for interaction = 0.45). The impact of AF on one-year mortality did 
not differ by sex, race or MI classification. Within strata defined by AF status as well as 
sex, race or MI classification, respectively, temporal trends in survival were similar; the 
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point estimates suggested improved survival among all strata, except men with AF, over 
the study period.  
A sensitivity analysis, excluding those who had a cardiac operative procedure 
performed during the index hospitalization, was performed and results were consistent 
with the primary analysis.  
 
9.5 DISCUSSION 
In this population-based sample of validated MI hospitalizations, the prevalence 
of concomitant AF in MI increased slightly from 1987 to 2009 and was approximately 
15% in the most recent years. The secular trend in the prevalence of AF in the setting of 
MI differed by MI classification; the prevalence of coexisting AF increased over time 
among NSTEMI and unclassified MIs and decreased among STEMIs. Co-occurrence of 
AF in the setting of MI was associated with an increased risk of death and this association 
did not differ by sex, race or MI classification. Finally, improvements in 1-year survival 
among MI patients were greater in those without AF compared to those with AF, but this 
difference was not statistically significant. 
The percent of patients with co-occurring AF increased over time among those 
with NSTEMI and unclassified MIs, while simultaneously decreasing among STEMIs. It 
is not surprising that AF was more common among NSTEMIs as these patients tend to be 
older and have more comorbidities.
192-194
 However, we adjusted for age group, sex, race, 
field center, MI classification, severity of MI and number of ICD-9 diagnosis codes. This 
is not the first study to report an increasing prevalence of AF complicating NSTEMI; in 
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the Worcester Heart Attack Study, the adjusted OR of having AF in the setting of 
NSTEMI was 1.96 (95% CI: 1.38 – 2.79) in 2005 compared to 1997, while in STEMI the 
corresponding OR was 1.53 (95% CI: 0.97 – 2.44).186 The reasons for this difference 
between STEMI and NSTEMI have not been fully elucidated. Potential explanations 
include that changes in patient characteristics over the study period led to more AF in 
NSTEMI than in STEMI patients, that changes in treatment strategies resulted in STEMI 
patients going directly to the catheterization lab for treatment and subsequently they were 
less likely to develop AF, or that AF impacts the ST segments on ECG which makes it 
more difficult to classify an event as STEMI in the presence of AF. 
 Regardless of the temporal trends, AF complicating MI is consistently associated 
with worse survival;
22,23,29,166,168
 in a meta-analysis of 23 studies that provided 
multivariable adjusted analyses, the pooled mortality OR associated with AF in MI 
patients was 1.46 (95% CI 1.35 – 1.58).23  Our results are consistent with previous 
studies. Given the independent negative impact of AF on survival following MI, the 
occurrence of AF in MI should not be viewed as a minor event relative to more severe 
complications like ventricular tachycardia, but should be recognized as a critical 
condition. To date, prognostic risk scores for MI ignore AF in determining the risk of 
death and therapeutic decisions.
195,196
 Further consideration of AF in prognostic scores is 
warranted, especially because prevalence of AF in the community is estimated to increase 
as the population ages,
2,3
 and because AF often complicates MI.
23,166
         
 Moreover, patients with AF complicating MI have unique treatment needs that are 
not fully understood. Aspirin is a cornerstone of acute MI therapy and dual antiplatelet 
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therapy (aspirin and clopidogrel) is considered the gold standard following percutaneous 
coronary intervention.
197
 However, the combination of oral anti-coagulants and 
antiplatelets is associated with a high frequency of major bleeding.
198
  Thus, the optimal 
treatment strategy is unclear when the risks of thromboembolism and bleeding are 
considered. The introduction of new oral anticoagulant agents, including dabigatran, 
rivaroxaban, and apixaban, for the prevention of thromboembolic complications in AF as 
well as for the treatment of acute coronary syndromes raise additional questions about the 
optimal treatment strategy.
199,200
  
There are several limitations of this study. The diagnosis of AF relied on ICD-9 
hospital discharge codes and is not otherwise adjudicated. Nonetheless, this method has 
been found to have acceptable validity within the cohort component of the ARIC Study, 
which uses identical methods to ascertain hospitalized AF events; in a sample of 125 
hospital discharge summaries with a first ICD-9 code for AF, 89% were confirmed based 
on ECGs performed during that hospitalization.
7
 Temporal trends in co-occurrence of AF 
and MI are based on the proportion of MIs in a given time with documented AF. It is 
possible that the trends would change if this analysis were based on rates of co-
occurrence, which would scale the results to account for changes in the size of the 
population. The onset of AF was unknown and we included both AF occurring before 
and during the MI hospitalization. However, in a prior study the occurrence of AF before 
or after MI was associated with an increase in mortality over no AF in MI patients.
22
 In 
our study, patients who developed AF after hospital discharge were not identified and 
would be misclassified. Nevertheless, there is a positive association between time from 
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incident MI to first-detected AF and risk of death;
22
 consequently, our reported 
association likely was underestimated. Coding practices likely have changed over time. 
In an effort to account for these changes, analyses were adjusted for the number of ICD-9 
codes.  
In conclusion, this study provides evidence that the co-occurrence of AF in the 
setting of MI has increased over time. The presence of AF was consistently associated 
with worse survival after MI throughout the study. The results highlight that temporal 
trends in MI survival in those with AF have been similar among groups defined by sex, 
race and MI classification. 
       63 
9.6 TABLES  
 
Table 9.1: Baseline characteristics of patients hospitalized with incident definite or probable myocardial infarction by event 
year groups in the Community Surveillance component of the Atherosclerosis Risk in Communities Study, 1987 – 2009 
  
1987 - 1990    
(n = 3330) 
1991 - 1994           
(n = 3735) 
1995 - 1998                 
(n = 3770) 
1999 - 2002                
(n = 3501) 
2003 - 2006                 
(n = 3215) 
2007- 2009                     
(n = 2499) 
Age, years 59.8 59.9 59.6 59.0 58.9 58.8 
Female, % 1140 (34) 1313 (35) 1380 (37) 1276 (36) 1144 (36) 955 (38) 
Community and race groups, % 
      Forsyth County, NC blacks 271 (8) 325 (9) 459 (12) 364 (10) 369 (11) 420 (17) 
Forsyth County, NC whites 966 (29) 1124 (30) 1174 (31) 975 (28) 899 (28) 763 (31) 
Jackson, MS blacks 286 (9) 388 (10) 432 (11) 579 (17) 582 (18) 397 (16) 
Jackson, MS whites 496 (15) 537 (14) 367 (10) 289 (8) 181 (6) 151 (6) 
Minneapolis, MN whites 701 (21) 724 (19) 668 (18) 743 (21) 749 (23) 433 (17) 
Washington County, MD whites 610 (18) 637 (17) 670 (18) 551 (16) 435 (14) 336 (13) 
Comorbidities, % 
      Hypertension 1807 (54) 2138 (57) 2215 (59) 2240 (64) 2053 (64) 1855 (74) 
Stroke 155 (5) 259 (7) 301 (8) 280 (8) 219 (7) 198 (8) 
Diabetes -- 641 (17) 1076 (29) 1043 (30) 1139 (35) 946 (38) 
PREDICT score
*
 6.2 6.5 6.5 5.7 5.7 6.8 
Presentation characteristics 
      Hospital arrival < 2 hours, % 995 (30) 1113 (30) 1143 (30) 1064 (30) 798 (25) 623 (25) 
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First systolic blood pressure, mm Hg 144.2 148.3 147.4 149.2 145.5 148.0 
First pulse rate, bpm 84.1 85.3 85.8 86.9 87.6 89.5 
Atrial fibrillation, % 351 (11) 489 (13) 513 (14) 471 (13) 527 (16) 366 (15) 
Myocardial infarction classification 
      ST-elevation myocardial infarction 793 (24) 1071 (29) 1038 (28) 689 (20) 512 (16) 517 (21) 
Non ST-elevation myocardial 
infarction 2214 (66) 2157 (58) 2221 (59) 2373 (68) 2326 (72) 1789 (72) 
Unclassified 323 (10) 506 (14) 510 (14) 438 (13) 377 (12) 194 (8) 
Continuous variables presented as mean 
Categorical variables presented as count (%) 
History of diabetes not routinely collected until 1991 (29) / 1992 (270) 
*Modified PREDICT score did not include kidney function 
Hospital arrival < 2 hours was determined based on duration from earliest symptom onset time to hospital arrival time 
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Table 9.2: Medication
*
 and therapeutic procedures during hospitalization with incident definite or probable myocardial 
infarction by event year groups in the Community Surveillance component of the Atherosclerosis Risk in Communities Study, 
1987 – 2009 
  
1987 - 1990    
(n = 3330) 
1991 - 1994           
(n = 3735) 
1995 - 1998                 
(n = 3770) 
1999 - 2002                
(n = 3501) 
2003 - 2006                 
(n = 3215) 
2007- 2009                     
(n = 2499) 
Medication, % 
      Aspirin 2251 (68) 3233 (87) 3358 (89) 3173 (91) 2846 (89) 2280 (91) 
β blockers 1549 (47) 2252 (60) 2671 (71) 2832 (81) 2796 (87) 2236 (89) 
Calcium channel blockers 2151 (65) 2197 (59) 1497 (40) 852 (24) 702 (22) 634 (25) 
ACE or angiotensin II inhibitors -- 664 (18) 1724 (46) 2162 (62) 2115 (66) 1624 (65) 
Warfarin 302 (9) 545 (15) 635 (17) 476 (14) 430 (13) 338 (14) 
Lipid-lowering medications -- -- 248 (7) 2047 (58) 2284 (71) 1829 (73) 
Antiplatelet agents other than aspirin -- -- 823 (22) 1992 (57) 2011 (63) 1504 (60) 
Procedures, % 
      Thrombolytic agents 737 (22) 998 (27) 708 (19) 366 (10) 52 (2) 52 (2) 
PCI 538 (16) 855 (23) 999 (27) 1202 (34) 1325 (41) 1020 (41) 
CABG 466 (14) 478 (13) 577 (15) 438 (13) 301 (9) 189 (8) 
*
On admission, during hospitalization, or at discharge
 
Thrombolytic agents include intracoronary and intravenous 
The following medications were not routinely collected until the year indicated in parentheses: ACE or angiotensin II inhibitors 
(1992), antiplatelet agents other than aspirin (1997) and lipid-lowering agents (1999)  
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Table 9.3: Odds ratios for 28-day and one-year all-cause mortality comparing patients with versus without atrial fibrillation in 
the setting of hospitalized incident definite or probable myocardial infarction in the Community Surveillance component of 
the Atherosclerosis Risk in Communities Study, 1987 – 2009 
  
28-Day   
Mortality 
One-Year 
Mortality 
  OR* (95% CI) OR (95% CI) 
Number of deaths, (%) 204 (1.0) 1431 (7.1) 
Model 1: Age, sex, race, field center and year 2.23 (1.13 - 4.42) 2.15 (1.63 - 2.83) 
Model 2: Model 1 + MI classification
t
 and # ICD-9 2.13 (1.06 - 4.29) 1.93 (1.45 - 2.58) 
Model 3: Model 2 + presentation characteristics 1.92 (0.92 - 4.02) 1.72 (1.26 - 2.35) 
Model 4: Model 3 + Medication  2.20 (0.97 - 4.99) 1.55 (1.12 - 2.12) 
Model 5: Model 3 + therapeutic procedures 1.71 (0.84 - 3.49) 1.56 (1.15 - 2.12) 
Model 6: Model 2 + presentation characteristics, medications and procedures 2.10 (0.94 - 4.70) 1.47 (1.07 – 2.01) 
*OR = odds ratio; Comparison of co-occurring atrial fibrillation and myocardial infarction (MI) to MI 
t
MI classification = ST-Elevation MI, non ST-Elevation MI and unclassified 
Presentation characteristics = first systolic blood pressure, first pulse and the modified PREDICT score 
Medications = aspirin, β blockers, Calcium channel blockers, ACE or angiotensin II inhibitors, warfarin, lipid-lowering medications 
and antiplatelet agents other than aspirin 
Therapeutic procedures = percutaneous coronary intervention and coronary artery bypass graft 
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Table 9.4: Temporal trends in 1-year all-cause mortality stratified by atrial fibrillation status among those hospitalized with 
incident definite or probable myocardial infarction in the Community Surveillance component of the Atherosclerosis Risk in 
Communities Study, 1987 – 2009. Results presented as odds ratios (OR)* of mortality per 5-year increment 
  Atrial Fibrillation No Atrial Fibrillation           
  n / N 
OR per 5-year 
Increment 
Interaction p-value 
(subgroup*year) n / N 
OR per 5-year 
Increment 
Interaction p-value 
(subgroup*year) 
Overall 367 / 2717 0.86 (0.60 - 1.21) -- 1063 / 17332 0.74 (0.62 - 0.88) -- 
       Men 229 / 1731 1.05 (0.64 - 1.70) 
0.32 
630 / 11110 0.72 (0.57 - 0.92) 
0.21 
Women 139 / 986 0.71 (0.43 - 1.19) 433 / 6222 0.82 (0.63 - 1.06) 
       Whites 249 / 2140 0.98 (0.68 - 1.41) 
0.33 
621 / 13036 0.84 (0.66 - 1.05) 
0.40 
Blacks 119 / 577 0.79 (0.42 - 1.45) 442 / 4296 0.63 (0.48 - 0.82) 
       STEMI 45 / 391 0.68 (0.32 - 1.44) 
0.63 
173 / 4228 0.71 (0.50 - 1.00) 
0.13 NSTEMI 245 / 1945 0.84 (0.57 - 1.24) 726 / 11136 0.73 (0.58 - 0.90) 
Unclassified 77 / 381 0.68 (0.32 - 1.44) 165 / 1968 0.59 (0.35 - 1.00) 
Overall, there was no statistical evidence that one-year survival over time differed between those with or without AF (p for interaction 
= 0.45) 
AF = atrial fibrillation 
*Adjusted for age, sex, race, field center, MI classification (STEMI/NSTEMI/Unclassified), number of ICD-9 codes, presentation 
characteristics (first systolic blood pressure, first pulse and MI severity), medications (aspirin, β blockers, Calcium channel blockers, 
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ACE or angiotensin II inhibitors, warfarin, lipid-lowering medications and antiplatelet agents other than aspirin), and therapeutic 
procedures (percutaneous coronary intervention and coronary artery bypass graft)  
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9.7 FIGURES 
 
Figure 9.1: Three-year mean AF prevalence in hospitalizations with incident definite or probable myocardial infarction 
overall and by subtypes (ST-Elevation myocardial infarction, non-ST-Elevation myocardial infarction, and unclassified) in the 
Community Surveillance component of the Atherosclerosis Risk in Communities Study, 1987 – 2009 
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10.0 MANUSCRIPT 2 – ASCERTAINMENT OF NEWLY-DIAGNOSED 
ATRIAL FIBRILLATION USING ACTIVE COHORT FOLLOW-UP VERSUS 
SURVEILLANCE OF CENTERS FOR MEDICARE AND MEDICAID SERVICES 
IN THE ATHEROSCLEROSIS RISK IN COMMUNITIES STUDY 
 
10.1 OVERVIEW 
Background: Increasingly, epidemiologic studies use administrative data to identify AF. 
Capture of incident AF is not well documented. We examined incidence rates and 
concordance of AF diagnosis based on active cohort follow-up versus surveillance of 
CMS data in the ARIC study. 
Methods and Results: ARIC cohort participants without prevalent AF enrolled in FFS 
Medicare, Parts A and B, for at least 12 continuous months between 1991 and 2009 were 
included. In ARIC cohort follow-up, annual telephone calls captured hospitalizations and 
deaths with incident AF diagnosis codes. For CMS claims, incident AF was defined by 
billed inpatient and outpatient diagnoses. Of 10,134 eligible participants, 738 developed 
AF according to both ARIC and CMS; an additional 93 and 288 incident cases were 
identified using only ARIC and CMS data, respectively. Incidence rates per 1,000 
person-years were 10.8 (95% CI: 10.1–11.6) and 13.6 (95% CI: 12.8–14.4) in ARIC and 
CMS, respectively; agreement was 96%; the kappa statistic was 0.77 (95% CI: 0.75–
0.80).  Yet, the additional CMS events did not alter observed associations between risk 
factors and AF. 
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Conclusions: Among those enrolled in FFS Medicare, AF incidence rates were slightly 
lower via active cohort follow-up versus CMS surveillance, because the latter included 
outpatient AF. Concordance of incident AF was high and associations without CMS were 
not biased. Drawbacks of CMS are its inapplicability to those <65 years and inability to 
capture AF for those with Medicare Advantage. 
 
10.2 INTRODUCTION 
Increasingly, administrative data are used for research purposes, including 
epidemiologic studies to identify patients with CVDs
201-205
 such as AF.
27
 The ability to 
efficiently and inexpensively access information on a large number of people makes 
administrative claims an appealing source of outcomes for epidemiologic research. 
However, the usefulness of this approach varies by numerous factors, including the 
disease algorithm chosen and the population studied.  Medicare data are often used but 
are limited to those ≥65 and not having supplemental health maintenance organization 
(HMO) coverage. High-performing algorithms have been developed to identify major 
CVDs.
201-205
 A recent systematic review of algorithms used to identify AF in 
administrative data, compared most often to medical records or physician review of 
records, reported a median PPV of 89% (range: 70% - 96%) and a median sensitivity of 
79% (range: 57% - 95%).
180
  
 Despite performance measures that indicate that administrative data could be a 
promising source for identifying AF patients, gaps exist concerning the appropriateness 
of this approach. A systematic review of 16 unique studies found that only one examined 
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the ability of administrative data to identify incident AF. In this single study, a physician 
reviewed a sample of 125 hospital discharge summaries with a first ICD-9 code for AF 
and ECGs performed during that hospitalization to determine the validity of using 
hospital discharge codes; the PPV for any AF was 89% and for incident AF was 62%.
7
  
Additionally, no study has compared the incidence or prevalence of AF using only 
inpatient or only outpatient claims compared to using both inpatient and outpatient 
claims. An important limitation of some cohort studies, including the ARIC and CHS 
cohorts, is reliance exclusively on inpatient claims to identify AF,
7,8
 which could result in 
under-ascertainment of AF. Furthermore, the majority of studies were performed in 
predominately white populations. The validity of utilizing administrative data also may 
vary by race/ethnicity, as one study performed a subgroup analysis among stroke patients 
and reported a lower sensitivity of AF ascertainment from ICD-9 codes compared to 
medical record review for blacks compared to whites.
7
  
In the present study we sought to address the limited knowledge regarding the 
usefulness of administrative data to determine AF incidence, the lack of inpatient and 
outpatient claims comparison, and the paucity of data in nonwhite populations. We 
compared overall and race-specific incidence rates of AF using the active ARIC cohort 
follow-up method with surveillance of CMS administrative Medicare claims data 
(inpatient only, outpatient only and both inpatient and outpatient claims). Additionally, 
we assessed concordance of AF diagnosis between the data sources and performed a 
descriptive analysis to identify factors associated with earlier diagnosis as well as 
concordance.  
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10.3 METHODS 
Data sources 
The ARIC study is a population-based prospective study of  CVD in a 
predominantly biracial cohort of 15,792 participants between 45 and 64 years of age at 
enrollment.
176
 From 1987 – 1989, participants were sampled from four US communities: 
Forsyth County, North Carolina; Jackson, Mississippi; northwest suburbs of Minneapolis, 
Minnesota; and Washington County, Maryland. Additional study exams occurred during 
three follow-up visits as well as annual telephone contact to obtain information about all 
hospitalizations and vital status, details of which have been reported previously.
7
  
The ARIC study has an Interagency Agreement with the CMS to obtain Medicare 
data for ARIC cohort participants. Participants are matched on social security number, 
sex, and date of birth. Of the 15,738 ARIC participants alive as of January 1, 1991, 
14,530 (92.3%) were matched successfully and linked to CMS Medicare claims. Matched 
participants are linked to inpatient, outpatient, and carrier files. The MedPAR file 
contains claims for inpatient services covered under Medicare Part A. The outpatient files 
contain claims for services covered under Medicare Part B, including institutional claims 
(Outpatient file) for outpatient services and noninstitutional physician claims (Carrier 
file). CMS claims for inpatient and outpatient services have been available for research 
since 1991.   
Study sample 
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For this analysis, ARIC cohort participants enrolled in FFS Medicare, both Parts 
A and B, for at least 12 continuous months between January 1, 1991, and December 31, 
2009, were eligible for inclusion (Figure 10. 1). Enrollment in FFS Medicare was 
necessary because Medicare Advantage insurance plans are not required to submit claims 
for beneficiaries and those enrolled in only Part A are known to have incomplete claims 
data. Participants whose race was not white or black and nonwhites from the Minneapolis 
and Washington County field centers were excluded due to small numbers. Additionally, 
those at the initial ARIC study exam with missing or unreadable ECG or prevalent AF 
were excluded. Furthermore, because we are interested in incident AF and CMS data 
were available for research beginning January 1, 1991, participants diagnosed with AF 
based on ARIC data before January 1, 1992 were excluded. In order to ascertain incident 
diagnoses, participants with AF diagnosed during the first year of FFS enrollment, from 
either ARIC or CMS data, were excluded. Participants enrolled in Medicare due to 
disability or certain covered medical conditions were not included in the study unless 
they met eligibility criteria after becoming age eligible (aged ≥ 65 years). Each center’s 
institutional review board approved the study and all participants provided informed 
consent. 
Definition of atrial fibrillation 
 Active ARIC cohort follow-up identifies AF cases through study visit ECGs, 
hospital discharge codes, and death certificates.
7
   However, for this analysis, AF cases 
obtained exclusively from study ECGs (n=4) were not included as AF events due to their 
subclinical nature and to ensure consistent methods of ascertainment between data 
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sources. Incident cases of AF were ascertained through hospital discharge codes, ICD-9 
codes 427.3, 427.31 or 427.32, in any position, and death certificates with ICD-10 code 
I48 or ICD-9 code 427.3x as the underlying cause of death. The date of AF incidence was 
defined as the date of first hospital discharge with an AF or AFL diagnosis, or death by 
AF, whichever occurred earlier.  
For MedPAR and outpatient CMS claims, incident AF was defined as an AF 
discharge diagnosis (ICD-9 code 427.3, 427.31 or 427.32), in any position, on a single 
inpatient claim or as a diagnostic code on two outpatient claims within 7 – 365 days. A 
minimum of two outpatient claims at least 7 days apart were required to reduce the 
likelihood of including “rule out” diagnoses and to improve algorithm specificity.27,182 
The incidence date of AF was defined as the discharge date for a MedPAR short-stay 
claim or the date of the second qualifying outpatient claim, whichever occurred earlier. 
Secondary CMS definitions of AF were restricted to only MedPAR claims criteria and 
only outpatient claims criteria. 
AF following cardiac operative procedures is fairly common.
206
 Therefore, in both 
active cohort follow-up and surveillance of CMS, an AF diagnosis occurring 
simultaneously with cardiac revascularization (ICD-9 code 36.31, 36.1) or other cardiac 
surgery involving heart valves or septa (ICD-9 code 35.32, 35.33, 35.39, 35.95, 35.1X, 
35.2X, 35.7X) during the index hospitalization, without a subsequent diagnosis of AF, 
was not considered an AF diagnosis. 
Assessment of covariates 
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 During the baseline ARIC study exam, standardized methods were used to collect 
data on age, race, sex, educational achievement, cigarette smoking, ethanol consumption, 
height, weight, blood pressure, antihypertensive medication use, diabetes mellitus, total 
cholesterol, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, 
triglycerides, and previous myocardial infarction, HF or coronary heart disease.
176
 An 
ECG Cornell voltage score >28 mm in men or >22 mm in women was considered 
evidence of left ventricular hypertrophy.
207
 
Statistical analysis 
We calculated person-years of follow-up as the date of study eligibility, following 
12 months of continuous enrollment in FFS Medicare without an AF diagnosis, to the 
date of AF diagnosis, death, loss to follow-up, cessation of FFS enrollment, or December 
31, 2009, whichever occurred earliest. Person-years of follow-up were attributed to age- 
(5 year age groups), sex- and race- (whites and blacks) specific groups. Age-, sex- and 
race-specific rates were calculated dividing the number of incident AF cases by the 
corresponding person-years of follow-up. In addition, age- and sex-standardized rates of 
incident AF for whites and blacks separately were calculated using the sex and age (65–
69 years, 70–74 years, 75–79 years and 80 years and older) person-time distribution of 
the eligible cohort.      
Concordance of incident AF events between ARIC follow-up and CMS 
surveillance was assessed with Cohen’s Kappa (Κ) statistic, a chance-adjusted measure of 
agreement.
208
 Due to inherent limitations of Kappa, percent agreement, overall, as well as 
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positive and negative agreement, were calculated to provide a more complete assessment 
of concordance.
209-211
  
A descriptive analysis, restricted to participants with incident AF ascertained in 
both ARIC and CMS, and with complete covariate data, was performed to determine the 
mean difference in incident date. Subsequently, linear regression was used to determine 
predictors of earlier diagnosis. Additionally, log-binomial regression, restricted to 
participants with AF ascertained from at least one data source, ARIC or CMS, and with 
complete covariate data was used to identify demographic and clinical factors associated 
with concordance. Age, sex and a composite race and center variable were retained in the 
linear and log-binomial regression models regardless of statistical significance.  Cox 
proportional hazards regression was used to determine the association between 
established risk factors and incident AF based exclusively on active ARIC cohort follow-
up; subsequently, cases of incident AF ascertained only from surveillance of CMS data 
were included to determine the impact of these additional events on the associations. All 
statistical analyses were performed with SAS, version 9.2 (SAS Institute, Cary, NC).  
 
10.4 RESULTS 
 Of the original 15,792 ARIC participants, our final analytic sample included 
10,134 participants who were initially free of AF and enrolled in FFS for at least 12 
continuous months between January 1, 1991 and December 31, 2009. It was notable that 
18,194 person-years available to ARIC had to be omitted because those participants were 
in Medicare Advantage and therefore had incomplete CMS claims.  To ensure 
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participants were free of AF, those diagnosed with AF within the first 12 continuous 
months of enrollment were excluded (Figure 10.1). A total of 831 incident AF diagnoses 
during 76,754 person-years of follow-up were ascertained from active ARIC follow-up. 
The corresponding figures from CMS surveillance were 1,026 (736 inpatient [MedPAR] 
and 827 outpatient) AF diagnoses during 75,596 (76,887 inpatient [MedPAR] and 76,293 
outpatient) person-years of follow-up. Baseline characteristics of the study sample 
stratified by source of AF diagnosis are shown in Table 10.1. Overall, the mean age at 
baseline, date of study eligibility, was 66.4 years (standard deviation 1.5 years) and 
women accounted for slightly over half and blacks for a quarter of the study sample. 
Among AF diagnoses ascertained only by active ARIC follow-up, 32% were among 
blacks, while among those ascertained only in surveillance of CMS, 13% were among 
blacks. Participants with AF diagnosed from both data sources had a higher prevalence of 
prior MI and HF compared to those with AF ascertained from only one source. 
AF incidence increased with age and was consistently higher among men and 
whites compared to women and blacks, respectively, regardless of the source of diagnosis 
(Figure 10.2). The age-, sex- and race-specific incidence rates were slightly higher based 
on CMS ascertainment of AF but followed a pattern similar to the rates based on active 
ARIC follow-up. Among participants with AF diagnosed in both data sources, 63% had 
identical dates of AF diagnosis from ARIC and CMS and nearly 75% had diagnoses 
within ± 30 days, based on a linear regression model with time between diagnosis dates 
in ARIC and CMS. Earlier ascertainment of AF by one system versus the other was not 
associated with any CVD risk factors, after accounting for sociodemographic factors. 
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After accounting for differences in the age and sex distribution of whites and blacks by 
standardizing the rates to the study sample (Table 10.2), the AF incidence rate based on 
ARIC ascertainment, per 1,000 person years, was 11.4 (95% CI: 10.5 – 12.2) and 8.6 
(95% CI: 7.1 – 10.0) among whites and blacks, respectively. The comparable rates from 
CMS surveillance of AF were 14.8 (95% CI: 13.8 – 15.8) and 8.9 (95% CI: 7.5 – 10.4) 
for whites and blacks, respectively. Using secondary CMS definitions of AF, restricted to 
only inpatient (MedPAR) claims criteria, the age- and sex-standardized rate per 1,000 
person-years among whites was 10.3 (95% CI: 9.5 – 11.1) and among blacks was 6.6 
(95% CI: 5.3 – 7.8); restricted to only outpatient claims criteria, the corresponding rates 
were 12.1 (95% CI: 11.2 – 13.0) and 6.4 (95% CI: 5.1 – 7.6) for whites and blacks, 
respectively. Utilizing the secondary CMS definition of AF, restricted to only inpatient 
(MedPAR) claims criteria, among participants with AF diagnosed in both sources, 90% 
of participants had AF diagnosed on the same day and 93% were within ± 30 days. When 
considering only outpatient claims criteria for CMS surveillance of AF compared to 
active ARIC follow-up, among participants with AF diagnosed in both sources, 61% of 
AF diagnoses occurred earlier in ARIC (hospital discharge date) compared to outpatient 
CMS surveillance. 
 Cohen’s Κ for overall concordance of incident AF diagnosis between ARIC 
cohort follow-up and CMS data was 0.77 (95% CI: 0.75 – 0.80) (Table 10.3).  Comparing 
hospital inpatient ascertainment of AF, the primary method of AF detection in ARIC, the 
Κ statistic improved to 0.85 (95% CI: 0.83 – 0.87). Race-specific Κ statistics were similar 
to the overall sample estimates (data not shown) for all CMS and inpatient (MedPAR) 
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comparisons. However, the K statistic for active ARIC follow-up versus CMS outpatient 
surveillance was lower among blacks, 0.56 (95% CI: 0.48 – 0.63). After accounting for 
age, sex and race/center, a descriptive analysis did not identify any factors associated 
with concordance between data sources.  
To explore the impact of including incident AF cases ascertained only in 
surveillance of CMS data, an analysis of the association between incident AF and the 
primary risk factors (age, male sex, white race, BMI, hypertension, diabetes, current 
smoking and prior heart disease) was performed. The HRs were very similar in a model 
based exclusively on active ARIC cohort follow-up methods compared to a model with 
the addition of incident AF ascertained from surveillance of CMS (Table 10.4) 
suggesting the omission of CMS ascertained (mostly outpatient) AF events does not bias 
the associations derived from active ARIC follow-up alone.   
 
10.5 DISCUSSION 
In this community-based prospective study, incidence rates of AF were slightly 
lower based on active ARIC follow-up compared to CMS surveillance. The rates by 
either method followed a similar pattern, increasing with age and consistently higher 
among whites and men compared to blacks and women, respectively. Concordance of 
incident AF between ARIC cohort follow-up and CMS data was very good,
208
 although 
19% more AF cases were identified from CMS largely due to outpatient ascertainment of 
AF. Furthermore, there appeared to be little bias in associations based only on active 
ARIC follow-up versus surveillance including CMS.  To our knowledge, this is the first 
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study to compare AF rates as well as concordance of diagnosis between data sources 
using only inpatient data, only outpatient data, and combined inpatient and outpatient 
data.
180
 
Overall, reliance exclusively on active ARIC cohort follow-up identified 831 
incident cases of AF while CMS surveillance yielded 1,026 incident AF events. 
Concordance between the two data sources was good with a Κ statistic of 0.77 (95% CI: 
0.75 – 0.80). As would be expected, because active ARIC follow-up relies exclusively on 
inpatient claims to identify AF, concordance improved when comparing only inpatient 
data. However, discrepancies persisted between the two data sources. Potential reasons 
for the discrepancies include that, among the 63 ARIC participants with AF ascertained 
from inpatient (MedPAR) CMS data but not ARIC data, some participants stopped 
participating in annual telephone follow-up for the ARIC study but continued to be 
followed by the ARIC study for fatal events. As a result, ARIC would not be able to 
identify hospitalizations for these participants occurring outside of the geographic 
catchment area of the four ARIC communities. Possible reasons for divergence in the 
opposite direction--AF obtained in ARIC data but not in CMS data--include that the 
participant was admitted at a Veterans Affairs Hospital where CMS does not have access 
to the claims and that ARIC data captures up to 26 diagnosis and procedure codes while 
CMS MedPAR data only include 10 diagnosis and 6 procedure codes. 
There are advantages and disadvantages of both active cohort follow-up and 
surveillance of CMS to identify incident AF. Advantages of utilizing active cohort 
follow-up include ascertainment of AF at younger ages (prior to Medicare eligibility) and 
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ability to identify AF regardless of type of insurance; disadvantages of this approach 
include missing outpatient diagnoses of AF and reliance on participants to report 
hospitalizations that occur outside of the study catchment area. The benefits of 
surveillance of CMS data include that outpatient AF diagnoses are obtained as are 
diagnoses for participants who stopped participating in cohort follow-up; disadvantages 
include lack of information on those <65 years as well as lack of claims during Medicare 
Advantage enrollment.  
Despite these opposing advantages and disadvantages, the results from the two 
methods were similar with comparable incidence rates, high concordance, and little 
evidence of bias of associations between AF and risk factors. These results can be 
interpreted several ways: supporting the exclusive use of active cohort follow-up, 
providing caution about the completeness of data from reliance on one method, and 
finding that two very different methods of AF ascertainment yielded similar results.  
There are several limitations of this study. Medicare Advantage plans are not 
required to submit claims on their beneficiaries; therefore, claims for ARIC participants 
during enrollment in Medicare Advantage were not included in the analysis. A total of 
18,194 person-years (19%) of follow-up were unobservable as a result of HMO 
enrollment (all other eligibility criteria were met) out of 97,740 total person-years. More 
importantly, person-years missed varied by center (Forsyth County, NC: 7,935, Jackson, 
MS: 1,640, Minneapolis, MN: 7,985, and Washington County, MD: 634).  This makes 
use of CMS alone impractical for ARIC follow-up. Although exclusion of participants 
with Medicare Advantage limits the generalizability of the study findings, the 
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concordance data are applicable to the FFS CMS population. Another drawback of ARIC 
is that it involves whites and blacks from only three and two communities, respectively, 
and might not be generalizable to all whites and blacks in the US. In active ARIC follow-
up, AF ascertainment relies primarily on hospital discharge codes and the diagnosis is not 
otherwise validated. However, this method has been found to have acceptable validity; in 
a sample of 125 hospital discharge summaries with a first ICD-9 code for AF, 111 cases 
(89%) were confirmed based on ECGs performed during that hospitalization.
7
 Finally, 
neither data source identified AF using a gold standard and consequently high 
concordance between the two data sources supports, but does not prove, validity of these 
approaches to identify incident AF. 
The present study also has several strengths. First, its large sample size, with a 
substantial black population, and long follow-up of study participants enabled race-
specific calculations through 2009. Most previous studies have been conducted in 
predominately white populations which is a limitation because some measures of validity, 
including PPV, are highly influenced by the prevalence of the disease in the source 
population, and blacks are known to have a lower risk of AF.
2,7,12,122
 This study afforded 
the opportunity to determine the usefulness of this approach in both whites and blacks. 
Second, only one prior study has assessed the ability of administrative data, compared to 
physician reviewed hospital discharge summaries with a first ICD-9 code for AF and 
ECGs, to identify incident AF events; the PPV for AF was 89% and for incident AF was 
62%.
7
 In the present study, concordance of prevalent AF diagnosis was similar to that of 
incident AF diagnosis (data not shown). The ability to identify incident AF events is 
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especially important for comparative effectiveness research, studies of healthcare 
utilization over the entire disease course of AF, and drug safety surveillance; for 
example, a comparative effectiveness research study might want to include only 
treatment-naïve participants in order to decrease biases associated with treatment 
effectiveness in observational studies. Third, claims data are limited with respect to 
clinical characteristics because their primary purpose is for reimbursement. In this study, 
the ARIC data were linked to CMS data and, as a result, information not available in 
claims data, such as detailed and validated demographic, behavioral and comorbid 
conditions measured using standardized methodology, were present and included in 
descriptive analyses.  
In conclusion, this study provides support for the potential value of utilizing 
multiple data sources to identify incident AF and suggests the need for caution about 
completeness of each data source. Nonetheless, two very different approaches to 
identifying incident AF produced similar results. Each approach has unique strengths and 
limitations and, when combined, could provide a more complete picture of newly-
diagnosed AF. Moving forward, the ARIC cohort and similar studies should evaluate 
how to incorporate Medicare and other administrative data in the ascertainment of 
outcomes, factoring in the data limitations regarding coverage and quality. 
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10.6 TABLES 
 
Table 10.1: Baseline
*
 (1987-89) characteristics of ARIC Study participants enrolled in Medicare fee-for-service, overall and by 
source of incident atrial fibrillation diagnosis 
  
Total                                            
(n = 10,134) 
ARIC Only                                      
(n = 93) 
CMS Only                                      
(n = 288) 
ARIC and CMS                          
(n = 738) 
No Incident AF 
Diagnosis                        
(n = 9015) 
Age, years 66.4 ± 1.5 66.7 ± 1.9 66.5 ± 1.6 66.6 ± 1.6 66.4 ± 1.5 
Women, % 57.0 46.2 42.4 45.4 58.5 
Black, % 26.0 32.3 13.2 15.3 27.2 
High school graduate, % 76.8 62.4 76.4 71.5 77.4 
Current smoker, % 23.2 30.1 22.2 29.3 22.6 
Current drinker, % 55.3 46.7 57.6 55.0 55.3 
BMI (kg/m
2
) 27.7 ± 5.2 28.8 ± 5.6 28.1 ± 5.1 28.6 ± 5.4 27.6 ± 5.2 
Hypertension, % 34.2 39.8 40.0 49.0 32.8 
Antihypertensive medication, % 25.0 25.0 31.9 37.1 23.8 
Diabetes mellitus, % 10.6 18.3 12.9 16.4 10.0 
Total cholesterol, mg/dL 216.6 ± 41.7 220.8 ± 49.6 217.2 ± 45.4 219.3 ± 39.5 216.3 ± 41.6 
LDL-c, mg/dL 139.0 ± 39.2 143.6 ± 47.4 141.8 ± 44.0 142.8 ± 35.6 138.5 ± 39.2 
HDL-c, mg/dL 52.1 ± 17.0 49.1 ± 14.5 49.4 ± 16.4 47.7 ± 15.6 52.5 ± 17.1 
Triglycerides, mg/dL 130.7 ± 85.3 140.5 ± 71.5 136.2 ± 100.9 147.8 ± 92.0 129.0 ± 84.1 
Left ventricular hypertrophy, % 1.8 2.2 2.9 3.7 1.6 
Previous myocardial infarction, % 3.4 3.2 6.6 9.5 2.8 
Heart failure, % 4.1 4.4 4.3 8.5 3.7 
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Coronary heart disease, % 4.1 3.3 9.1 11.4 3.4 
ARIC = Atherosclerosis Risk in Communities 
CMS = Centers for Medicare and Medicaid Services 
Continuous variables presented as mean ± standard deviation (SD) 
*Baseline age is age upon meeting enrollment criteria for the present analysis. All other characteristics are from the initial ARIC study 
exam (1987 – 1989) 
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Table 10.2: Race-specific incidence rates of atrial fibrillation among Atherosclerosis 
Risk in Communities Study participants enrolled in Medicare fee-for-service by 
source of diagnosis  
Source of Diagnosis 
Whites                                                       
(n = 7504) 
Blacks                 
(n = 2630) 
ARIC Data 
  Incident AF (n/person years) 688 / 58606.8 143 / 18146.7 
Unadjusted incidence rate
*
 11.7 (10.9 - 12.7) 7.9 (6.7 - 9.3) 
Age- and sex-standardized incidence rate
*
 11.4 (10.5 - 12.2) 8.6 (7.1 - 10.0) 
All CMS Data
†
 
  Incident AF (n/person years) 875 / 57528.8 151 / 18067.6 
Unadjusted incidence rate 15.2 (14.2 - 16.3) 8.4 (7.1 - 9.8) 
Age- and sex-standardized incidence rate 14.8 (13.8 - 15.8) 8.9 (7.5 - 10.4) 
Inpatient (MedPAR) Data 
  Incident AF (n/person years) 623 / 58677.7 113 / 18209.6 
Unadjusted incidence rate 10.6 (9.8 - 11.5) 6.2 (5.2 - 7.5) 
Age- and sex-standardized incidence rate 10.3 (9.5 - 11.1) 6.6 (5.3 - 7.8) 
Outpatient CMS Data 
  Incident AF (n/person years) 721 / 58094.2 106 / 18198.5 
Unadjusted incidence rate 12.4 (11.5 - 13.4) 5.8 (4.8 - 7.0) 
Age- and sex-standardized incidence rate 12.1 (11.2 - 13.0) 6.4 (5.1 - 7.6) 
*Rates per 1,000 person years (95% confidence intervals) 
†Includes inpatient (MedPAR) and outpatient diagnosis of atrial fibrillation 
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Table 10.3: Overall concordance of incident atrial fibrillation diagnosis based on Atherosclerosis Risk in Communities (ARIC) 
data and Centers for Medicare and Medicaid Services (CMS) data 
    All CMS Inpatient (MedPAR) CMS Outpatient CMS 
  AF No AF Total AF No AF Total AF No AF Total 
ARIC 
Cohort 
Follow-
up 
AF 738 93 831 673 158 831 563 268 831 
No AF 288 9015 9303 63 9240 9303 264 9039 9303 
Total 1026 9108 10134 736 9398 10134 827 9307 10134 
Kappa  0.77 0.85 0.65 
95% confidence interval (0.75 – 0.80) (0.83 – 0.87) (0.62 – 0.68) 
% agreement 96 98 95 
% positive agreement 66 75 51 
% negative agreement 96 98 94 
Data are limited to participants enrolled in Medicare fee-for-service 
All CMS includes MedPAR and outpatient claims 
Inpatient CMS includes MedPAR claims 
Outpatient CMS includes outpatient and carrier claims 
% agreement calculated as the number of participants with consistent classification of diagnosed AF from active ARIC cohort follow-
up and surveillance of CMS divided by the total number of observations and converted to a percent 
% positive agreement calculated as the number of participants classified as having AF based on both active ARIC cohort follow-up 
and surveillance of CMS, conditional on being classified as having AF from at least one source, and converted to a percent 
% negative agreement calculated as the number of participants classified as not having AF based on both active ARIC cohort follow-
up and surveillance of CMS, conditional on being classified as not having AF from at least one source, and converted to a percent 
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Table 10.4: Beta estimates for primary risk factors of the hazard of incident atrial fibrillation (AF) using active 
Atherosclerosis Risk in Communities (ARIC) follow-up compared to active ARIC follow-up plus surveillance of Centers for 
Medicare and Medicaid Services (CMS) data 
  Active ARIC Follow-Up 
Active ARIC Follow-Up 
and CMS Surveillance 
  
Beta 
Estimate 
Standard 
Error 
Beta 
Estimate 
Standard 
Error 
Age, years 0.10 0.004 0.10 0.004 
Female (Male) -0.45 0.05 -0.47 0.04 
Black (White) -0.53 0.06 -0.57 0.06 
BMI, kg/m
2
 0.05 0.005 0.04 0.004 
Hypertensive (Normotensive) 0.40 0.05 0.38 0.05 
Diabetic (Non diabetic) 0.43 0.06 0.41 0.06 
Current smoker (Ever, never smoker) 0.63 0.05 0.59 0.05 
Prior heart disease (No prior heart disease)
*
 0.67 0.07 0.67 0.06 
Exposed (Referent)  
*Prior heart disease defined as the presence of heart failure, myocardial infarction or coronary heart disease 
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10.7 FIGURES 
 
Figure 10.1: Derivation of study sample  
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Figure 10.2: Age-, sex- and race-specific incidence rates of atrial fibrillation by 
source of diagnosis  
 
CMS includes inpatient (MedPAR) or outpatient diagnosis of atrial fibrillation 
1,000 p-y = 1,000 person-years  
Vertical bars represent 95% confidence intervals 
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11.0 MANUSCRIPT 3 – IMPACT OF ATRIAL FIBRILLATION ON 
HEALTHCARE UTILIZATION IN THE COMMUNITY: THE 
ATHEROSCLEROSIS RISK IN COMMUNITIES STUDY 
 
11.1 OVERVIEW 
Background: AF is associated with increased risk of hospitalizations. However, little is 
known about the impact of AF on non-inpatient healthcare utilization or about sex or race 
differences in AF-related utilization. We examined rates of inpatient and outpatient 
utilization by AF status in the ARIC study. 
Methods and Results: ARIC cohort participants with incident AF enrolled in FFS 
Medicare, Parts A and B, for at least 12 continuous months between 1991 and 2009 were 
matched on age, sex, race and center to up to three participants without AF. Healthcare 
utilization was ascertained from inpatient and outpatient Medicare claims and classified 
based on primary ICD-9 code. The analysis included 944 AF and 2,761 non-AF 
participants. The average numbers of days hospitalized per year were 13.1 (95% CI: 11.5-
15.0) and 2.8 (95% CI: 2.5-3.1) for those with and without AF, respectively. The 
corresponding numbers of outpatient claims per year were 53.2 (95% CI: 50.4-56.1) and 
23.0 (95% CI: 22.2-23.8) for those with and without AF, respectively. Most utilization in 
AF patients was attributable to non-AF conditions, particularly other-CVD-related 
reasons; the adjusted rate ratio for days hospitalized per year for other-CVD-related 
reasons was 4.76 (95% CI: 3.51 – 6.44) for those with compared to those without AF. 
There was suggestive evidence that sex modified the association between AF and 
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inpatient utilization, with AF related to greater utilization in women than men. The 
association between AF and healthcare utilization was similar in whites and blacks. 
Conclusions: This study highlights the considerably greater healthcare utilization 
(inpatient and outpatient) among those with AF; the differential in utilization due to 
other-CVD-related reasons was substantial. In addition to rate or rhythm treatment, 
management of AF should also focus on the accompanying cardiovascular comorbidities.  
 
11.2 INTRODUCTION 
In the US, the most recent annual national data reported 479,000 hospitalizations 
with AF as the primary diagnosis.
31
 Hospitalizations with AF as the primary diagnosis 
increased by 34 percent from 1996 to 2001.
36
 In addition to hospitalizations, outpatient 
burden is also high with five million physician office visits, 276,000 emergency 
department visits, and 234,000 hospital outpatient visits attributed to AF in the US in 
2001.
212
 AF patients are known to have many comorbidities: more than half of the AF 
burden can be explained by having at least one non-optimal risk factor, such as high 
blood pressure, elevated BMI, diabetes mellitus, cigarette smoking, or prior cardiac 
disease.
70
 Furthermore, AF is a major cause of other cardiovascular morbidity, including 
stroke,
18,19
 HF
20,21
 and acute MI
22,23
 as well as mortality.
26
 Healthcare utilization among 
AF patients is clearly significant from both an economic and clinical perspective, 
however it is unknown whether this utilization is due to AF itself, or due to comorbidities 
which are common among AF patients.  
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Administrative claims data indicate that, compared to age- and sex- matched 
beneficiaries without AF, those with AF had twice as many hospitalizations during the 
12-month period following initial AF diagnosis.
30
 A more granular analysis of 
hospitalizations conducted among Olmsted County, MN, residents diagnosed with AF 
between 1980 and 2000 reported that the primary reasons for first hospitalization 
following AF diagnosis were due to AF (26.4%), HF (21.7%), coronary or peripheral 
arterial causes (21.6%), and thromboembolic events (10.5%).
213
 In addition to 
hospitalizations, there is evidence of increased healthcare utilization in terms of surgery, 
clinic visits, phone contacts, specialist referrals, laboratory tests, and prescriptions among 
patients with AF compared to matched controls.
214
  
While the overall clinical burden of AF is substantial, sex and race disparities in 
access to and quality of healthcare among AF patients exist. Data from the National 
Center for Health Statistics revealed that, even after adjustment for confounders, among 
AF patients, women were less likely to receive warfarin compared to men.
215
  Among 
patients with atrial flutter, the odds of conversion therapy (procedure or medication) were 
0.84 among women compared to men (95% CI: 0.79 – 0.90).216 In the REasons for 
Geographic And Racial Differences in Stroke (REGARDS) Study, a national population-
based longitudinal study, the odds of blacks knowing they had AF were 0.33 compared to 
whites (95% CI: 0.20 – 0.52).217 Moreover, among those who were aware of their AF, the 
odds of blacks being treated with warfarin were 0.25 that of whites (95% CI: 0.13 – 
0.60).
217
 Among elderly Medicare beneficiaries with AF, racial disparities in measures of 
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quality of care remained after adjustment for potential confounding factors; blacks had 
poorer quality of care compared to whites.
218
  
Given the substantial and increasing burden of AF on healthcare utilization, the 
limited knowledge about inpatient and non-inpatient utilization, and the lack of sex- and 
race-specific data, we sought to heighten understanding of how AF patients utilize 
healthcare and to provide data that can be used to allocate adequate resources for the care 
of AF patients. Specifically, we compared healthcare utilization (inpatient or outpatient) 
and primary reason (AF-related, other-CVD-related, and non-CVD related) for seeking 
medical care among ARIC Study participants with AF to those without AF. We also 
described differences in utilization by sex and race.  
 
11.3 METHODS 
Data sources 
The ARIC study is a population-based prospective study of  CVD in a cohort of 
15,792 black and white participants between 45 and 64 years of age at enrollment in 
1987-1989.
176
 Participants were sampled from four US communities: Forsyth County, 
North Carolina; Jackson, Mississippi, northwest suburbs of Minneapolis, Minnesota; and 
Washington County, Maryland. Additional participant contact has occurred through four 
follow-up clinic visits as well as annual telephone contact to obtain information regarding 
all hospitalizations and vital status, details of which have been reported previously.
7
  
The ARIC study has an Interagency Agreement with the CMS to obtain Medicare 
data for ARIC cohort participants. Participants are matched on social security number, 
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sex, and date of birth. The finder file included 15,738 ARIC participants, of which 14,530 
(92.3%) were matched successfully and linked to CMS Medicare claims. Data for 
participants whom matched successfully were linked to inpatient, outpatient and carrier 
files. The MedPAR file contains claims for inpatient services covered under Medicare 
Part A. The outpatient files contain claims for services covered under Medicare Part B, 
including institutional claims (Outpatient file) for outpatient services and noninstitutional 
physician claims (Carrier file). CMS claims for inpatient and outpatient services have 
been available for research since 1991.   
Study sample 
For this analysis, ARIC cohort participants enrolled in FFS Medicare, both Parts 
A and B, for at least 12 continuous months between January 1, 1991, and December 31, 
2009, were eligible for inclusion; for participants with multiple FFS enrollment periods 
(n = 647), only the first was included (Figure 11.1). Medicare FFS enrollment was a 
necessary requirement because Medicare Advantage insurance plans are not required to 
submit claims for beneficiaries. Additionally, those enrolled in only Part A (FFS) do not 
have claims data for Part B services (e.g., outpatient visits and physician visits). 
Participants whose race was not white or black and nonwhites from the Minneapolis and 
Washington County field centers were excluded due to small numbers. Both active ARIC 
cohort follow-up and surveillance of CMS data were used to identify and exclude all 
participants with prevalent AF. As such, based on initial ARIC study exam, participants 
with missing or unreadable ECG and those with prevalent AF on the baseline ECG were 
excluded. We were interested in incident AF, therefore utilizing all available information 
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from ARIC and CMS we excluded participants diagnosed with AF prior to January 1, 
1992 (CMS data were available for research from January 1, 1991, forward), participants 
with AF diagnosed prior to FFS enrollment or during the first year of FFS enrollment, 
and participants who stopped participating in ARIC follow-up. Participants enrolled in 
Medicare due to disability or certain covered medical conditions were not included in the 
study unless they met study eligibility criteria after becoming age eligible (aged ≥ 65 
years). Participants who died on the date of AF diagnosis were excluded.  
Participants with incident AF diagnosed based on CMS Medicare data during 
their initial FFS enrollment period were matched to up to three ARIC participants without 
AF based on age (within two years), sex, race and field center; matching was utilized to 
account for strong confounders and was performed with the SAS macro, gmatch, 
developed at the Mayo Clinic.
219
 Three matches were found for 93 percent of participants 
with AF. Of the 3,737 participants, 3,705 (944 with AF and 2,761 without AF) had 
complete covariate information and comprised our final sample. Each center’s 
institutional review board approved the study and all participants provided informed 
consent. 
Definition of atrial fibrillation 
Incident cases of AF were ascertained through MedPAR and outpatient CMS 
claims; incident AF was defined as an AF discharge diagnosis, ICD-9 code of 427.3, 
427.31 or 427.32, in any position, on a single short-stay inpatient (MedPAR) claim or on 
two outpatient claims within 7 – 365 days. A minimum of two outpatient claims at least 7 
days apart were required to reduce the likelihood of including “rule out” diagnoses and to 
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improve the algorithm specificity.
27,182
 The incidence date of AF was defined as the 
discharge date for a MedPAR short-stay claim or the date of the second qualifying 
outpatient claim, whichever occurred earliest. AF following cardiac operative procedures 
occurs frequently.
206
 Accordingly, AF diagnosis occurring simultaneously with cardiac 
revascularization (ICD-9 code 36.31, 36.1) or other cardiac surgery involving heart 
valves or septa (ICD-9 code 35.32, 35.33, 35.39, 35.95, 35.1X, 35.2X, 35.7X) during the 
index hospitalization, without a subsequent AF diagnosis, was not included. 
Definition of healthcare utilization 
 Healthcare utilization was ascertained from short-stay inpatient (MedPAR) and 
outpatient (Outpatient and Carrier files) CMS Medicare claims. Each claim was classified 
based on the primary discharge diagnosis code as AF-related (ICD-9 code 427.3x), other-
CVD-related (ICD-9 code 390 – 459) excluding AF, and non-CVD-related (all other 
valid ICD-9 codes). Claims with an invalid or missing primary diagnosis code were 
classified based on the first-listed usable diagnosis code. Length of hospitalization was 
taken into account for inpatient healthcare utilization by calculating length of stay (LOS). 
Multiple claims for the same date of service with identical diagnosis(es) code(s) were 
counted as one claim. 
Assessment of covariates 
 During the baseline ARIC study exam, standardized methods were used to collect 
data on age, race, sex, educational achievement, cigarette smoking, ethanol consumption, 
height, weight, blood pressure, antihypertensive medication use, diabetes mellitus, total 
cholesterol, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, 
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triglycerides, previous myocardial infarction, HF or coronary heart disease.
176
 An ECG 
Cornell voltage >28 mm in men or >22 mm in women was considered evidence of left 
ventricular hypertrophy.
207
 Data on these covariates were updated during additional 
ARIC study exams. Behavioral and clinical characteristics were updated to reflect closest 
values preceding AF diagnosis (for those with incident AF) or date of matching (for those 
without incident AF). 
Statistical analysis 
Person-years of follow up were calculated as the date of incident AF diagnosis 
(for those with incident AF) or the date matched (for those without incident AF), until the 
date of disenrollment in FFS Medicare, death or December 31, 2009, whichever occurred 
earliest. The annualized rate of inpatient (MedPAR) utilization was calculated by 
dividing the total number of days hospitalized by the corresponding person-years of 
follow-up, which can be interpreted as the average annual number of days hospitalized 
per person. The annualized rate of outpatient utilization was calculated by dividing the 
total number of unique claims per date of service by the corresponding person-years of 
follow-up. Negative binomial regression models were used to calculate rates and rate 
ratios of inpatient (MedPAR) and outpatient utilization comparing those with and without 
AF; models include an offset of log follow-up time to account for differential follow-up. 
Covariate data were updated to reflect the closest ARIC exam preceding AF diagnosis or 
the matched reference date for those without AF. Sex- and race-specific rates of 
healthcare utilization (inpatient and outpatient) also were calculated. The rate of 
utilization, classified based on the primary diagnosis code as AF, other-CVD, and non-
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CVD reasons, was calculated with the same approach as above for inpatient and 
outpatient utilization.  A descriptive analysis, restricted to hospitalizations for other-
CVD-related reasons and stratified by AF status and sex, was performed to identify the 
primary reasons for and rates of hospitalization.  
Pre-specified 2-way multiplicative interactions of healthcare utilization (inpatient 
[MedPAR] and outpatient considered separately) with sex and race were examined. A 
subgroup analysis, restricted to matched AF and non-AF participants with similar 
propensity scores, was performed. All statistical analyses were performed with SAS, 
version 9.2 (SAS Institute, Cary, NC). 
 
11.4 RESULTS 
Of the original 15,792 ARIC participants, our final analytic sample included 
3,705 participants (944 with AF and 2,761 without AF) who were enrolled in FFS 
Medicare for at least 12 continuous months between January 1, 1991 and December 31, 
2009. Characteristics of the study sample, stratified by AF status and updated to reflect 
closest ARIC study exam values preceding AF diagnosis or matching, are shown in Table 
11.1. Overall, the mean age at AF diagnosis or matching was 73.3 years (standard 
deviation 4.7 years) and women comprised approximately 45 percent and blacks nearly 
15 percent of the study sample; the distribution of these characteristics was similar 
among those with and without AF. Participants with AF were more likely to be current 
smokers, have higher body mass indices, hypertension, diabetes mellitus, left ventricular 
hypertrophy, HF and coronary heart disease. 
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 During a mean follow-up of 4.1 years, there were 2,615 hospitalizations among 
the 944 participants with AF; the median LOS was 5 days (interquartile range [IQR]: 3 - 
9). Among the 2,761 without AF, there were 3,005 hospitalizations during a mean 
follow-up of 4.2 years. The median LOS was 5 days (IQR: 3 - 8). The unadjusted days 
per year in the hospital were 13.1 (95% CI: 11.5 – 15.0) and 2.8 (95% CI: 2.5 – 3.1) for 
participants with and without AF, respectively (Table 11.2). After accounting for 
matching criteria, the number of days hospitalized per year was 4.80 (95% CI: 3.99 – 
5.78) times higher among participants with AF compared to those who remained free of 
AF. After adjustment for potential confounders, the rate of days in the hospital was 3.85 
(95% CI: 3.20 – 4.62) times greater, among those with AF. Healthcare utilization in the 
outpatient setting was higher among participants with AF compared to those without AF 
(Table 11.2); the median number of claims during follow-up was 122 ([IQR: 47 – 229.5) 
for those with AF and 50 (IQR: 17 – 114) for those without AF, based on unique claims 
per date of service. The unadjusted annual rate of outpatient utilization was 53.2 (95% 
CI: 50.4 – 56.1) and 23.0 (22.2 – 23.8) for those with and without AF, respectively. After 
accounting for matching criteria and other potential confounders, the rate ratio for 
outpatient utilization remained significantly greater among those with AF compared to 
those without AF (rate ratio: 2.13, 95% CI: 1.99 – 2.28).  
The interaction of sex with AF in the assessment of inpatient (MedPAR) 
healthcare utilization was of borderline statistical significance (p = 0.07), while the 
interaction was not significant for outpatient utilization (p = 0.33). The unadjusted rate of 
inpatient (MedPAR) healthcare utilization was highest for women with AF (Table 11.3), 
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15.6 per year (95% CI: 12.8 – 19.0), and lowest for women without AF, 2.6 (95% CI: 2.2 
– 3.0). Yet, after adjustment for matching criteria and additional potential confounders, 
the rate ratio for days hospitalized per year was similar among women and men without 
AF (Figure 11.2); among women, the rate ratio among those with AF compared to those 
without AF was 4.75 (95% CI: 3.56 – 6.34), while among men the corresponding rate 
ratio was 3.26 (95% CI: 2.56 – 4.15).  
The healthcare utilization following AF diagnosis did not differ significantly 
between whites and blacks for inpatient (MedPAR) (p for interaction = 0.90) or 
outpatient utilization (p for interaction = 0.16). Blacks with AF had the highest 
unadjusted rate of inpatient (MedPAR) utilization (rate: 17.4; 95% CI: 11.9 – 25.6) and 
outpatient utilization (rate: 53.7; 95% CI: 45.6 – 63.4) (Table 11.4). 
Among participants with AF, the unadjusted annual rate of days hospitalized with 
AF as the primary diagnosis code was 0.5 (95% CI: 0.3 – 0.7). The annual rate of days 
hospitalized for other-CVD-reasons was 4.3 (95% CI: 3.5 – 5.2) among those with AF 
and 0.8 (95% CI: 0.6 – 0.9) among those without AF (Table 11.5). After adjustment for 
matching criteria and other potential confounders, the adjusted rate ratio for days 
hospitalized per year for other-CVD-related reasons was 4.76 (95% CI: 3.51 – 6.44) for 
those with compared to those without AF. The magnitude of the difference was smaller 
for non-CVD-related hospitalized days. Outpatient utilization followed a similar pattern; 
the magnitude of the difference between those with AF and those without AF was 
greatest for other-CVD-related reasons (adjusted rate ratio: 2.46 [95% CI: 2.24 – 2.70]).  
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A sex-specific analysis of type (inpatient or outpatient) and primary reason for 
healthcare utilization (AF-related, other-CVD-related or non-CVD-related) revealed that 
other-CVD-related hospitalization days was the driving difference for sex differences in 
utilization (Table 11.6); the unadjusted rate of days hospitalized per year for other-CVD-
related reasons was 2.7 (95% CI: 2.1 – 3.4) and 1.1 (95% CI: 0.8 – 1.3) for men with and 
without AF, respectively. The corresponding values for women with and without AF 
were 6.6 (95% CI: 4.8 – 9.1) and 0.5 (0.3 – 0.6), respectively. The adjusted rate ratio for 
annual days hospitalized due to other-CVD-related causes was 11.94 (95% CI: 7.08 – 
20.13) for women with AF compared to those without AF, while the corresponding rate 
ratio was 2.41 (95% CI: 1.67 – 3.47) for men. A descriptive analysis revealed that 
cerebrovascular disease was the leading cause of non-AF CVD-related hospitalizations 
for both men and women without AF, 20.4 and 13.9, per 1,000 person-years, 
respectively. Among those with AF, however, the rate of non-AF CVD-related 
hospitalization was greatest for HF, 45.1 and 59.2, per 1,000 person-years, for men and 
women, respectively (Table 11.7).  
 In a subgroup analysis, restricted to matched AF and non-AF participants with 
similar propensity scores, the primary results were corroborated. The unadjusted days per 
year in the hospital were 9.4 (95% CI: 7.7 – 11.6) and 2.1 (95% CI: 1.6 – 2.8) for 
participants with and without AF, respectively (Table 11.8). After adjustment for 
potential confounders, the number of days hospitalized per year was 4.90 (95% CI: 3.51 – 
6.85) times higher among participants with AF compared to those who remained free of 
AF. In the outpatient setting, the unadjusted annual rate of utilization was 47.8 (95% CI: 
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43.9 – 52.0) and 21.9 (19.7 – 24.4) for those with and without AF, respectively. Based on 
the primary diagnosis code, in the fully adjusted model, the rate ratio for days 
hospitalized per year for other-CVD-related reasons was 6.30 (95% CI: 3.62 – 10.95) for 
those with AF compared to those without AF (Table 11.9). The adjusted rate ratio for 
other-CVD-related reasons in the outpatient setting was 2.70 (95% CI: 2.26 – 3.24) for 
those with compared to those without AF.  
 
11.5 DISCUSSION 
 In this sample of AF patients and matched controls from a community-based 
prospective study, rates of healthcare utilization, both inpatient (MedPAR) and 
outpatient, were substantially higher among participants with AF compared to those 
matched with cases and without AF. There was modest evidence of sex modifying the 
association between AF and inpatient (MedPAR) utilization; AF was associated with 
higher inpatient utilization in women than in men. In both the inpatient and outpatient 
setting, healthcare utilization was greatest for non-CVD-related reasons for those with as 
well as those without AF. However, the magnitude of the difference in utilization 
between those with and without AF was greatest for other-CVD-related reasons; this 
difference was especially pronounced for days hospitalized among women. 
 Overall, our findings underscore the high prevalence of cardiovascular 
comorbidities, particularly HF, triggering healthcare utilization among AF patients. At 
the time of AF diagnosis or matching, HF was almost three times more prevalent in AF 
patients compared to matched participants. The prevalence of other comorbidities, 
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including hypertension, diabetes, and coronary heart disease, were significantly higher 
among AF patients compared to the non-AF matched controls. Although AF has long 
been thought of as an electrical conduction problem, the high prevalence of 
cardiovascular comorbidities and the higher rate of healthcare utilization among those 
with AF, especially for other-CVD-related reasons, provide evidence that AF should not 
be considered just as an electrical problem, but as a marker of underlying vascular 
disease and overall cardiovascular risk. A Danish nationwide study reported that, within 
each age group, hospitalization rates for CVD and non-CVD admissions were higher 
among those with AF compared to those without AF.
220
 Furthermore, a 30-year follow-up 
of Olmsted County, Minnesota, residents diagnosed with lone AF, considered to be 
purely an electrical conduction problem, revealed that those with AF had slightly 
elevated risk of developing HF or a cerebrovascular event compared to the age- and sex-
matched Minnesota population.
221
 Moreover, in a contemporary anticoagulated AF 
population, 90% of deaths were due to reasons other than stroke;
222
 corroborating the 
impact of cardiovascular comorbidities on mortality reported from the AFFIRM
223
 and 
the Atrial Fibrillation and Congestive Heart Failure (AF-CHF) trials.
224
 In the present 
study, the associations between AF and inpatient (MedPAR) and outpatient healthcare 
utilization remained significant, but were attenuated, after adjusting for comorbidities. 
The overall adjusted rate ratio for days hospitalized due to other-CVD-reasons was 4.76 
(95% CI: 3.51 – 6.44) among those with AF compared to those without AF; the 
corresponding adjusted rate ratio for outpatient utilization was 2.46 (95% CI: 2.24 – 
2.70). This suggests that it is not just the presence of AF that causes healthcare 
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utilization, but the company it keeps— hypertension, diabetes mellitus, HF and coronary 
heart disease—that contributes, in part, to higher rates of healthcare utilization among AF 
patients. Our results underline the importance of adequate management and control of 
these comorbidities. However, despite the attenuation with adjustment for comorbidities, 
healthcare utilization remained substantially greater among those with AF, indicating 
considerable additional medical demand among this subset of the population.   
 In addition to the burden placed on the healthcare system, it is important to 
consider the burden of AF to the patient.
225,226
 Based on this study, the median number of 
days hospitalized per year for those with AF was 10, compared with zero among those 
without AF. Furthermore, outpatient utilization was approximately two and one half 
times greater among those with AF. This considerably higher utilization impacts quality 
of life for the patient and his/her caregivers.
227
 
 There was suggestive evidence of sex modifying the association between AF and 
inpatient (MedPAR) healthcare utilization; the differential utilization was most 
pronounced for other-CVD-related hospitalizations. Prior studies found the relative risk 
for cardiovascular events, including stroke, were higher among women with AF 
compared to men.
91,228,229
 Lower rates of anticoagulation in women compared to men, 
particularly among the elderly, have been implicated as an important factor.
230-232
 
However, a recent study suggests that elderly women, especially those aged ≥75, are at 
increased risk of stroke compared to elderly men, irrespective of their risk profile or 
warfarin use.
233
 The mechanisms underlying the increased relative risk of stroke among 
women compared to men with AF have not been fully elucidated; potential reasons for 
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this sex difference include hormonal factors, physiology, and psychosocial factors. 
Despite published disparities in AF treatment between whites and blacks,
217,218,234
 our 
study did not identify a differential impact of AF by race on inpatient (MedPAR) or 
outpatient utilization. However, the number of blacks with AF was small (n = 131) and 
from just two geographic areas, so it is possible that our study was underpowered to 
detect a difference. 
There are several limitations of this study. The CMS Medicare files for ARIC 
analysis did not contain line items and therefore multiple claims for the same date of 
service with identical diagnosis(es) code(s) could not be included in this study. Without 
the line items, it is impossible to know if the claims are for multiple services (lab, x-ray, 
physician) related to the same condition or for the same claim submitted multiple times. 
By excluding all claims with identical diagnostic codes for the same date of service, our 
estimates are conservative and, if anything, underestimate healthcare utilization. 
Additionally, our study had to be restricted to FFS Medicare enrollment windows 
because Medicare Advantage plans are not required to submit claims on their 
beneficiaries. Although exclusion of Medicare Advantage enrollment windows limits the 
generalizability of study findings, the results are applicable to the FFS Medicare 
population. A weakness of the ARIC study is that it includes whites and blacks from only 
three and two communities, respectively, and might not be generalizable to all whites and 
blacks in the US. Lastly, due to small numbers, the power to detect significant effect 
modification by sex or race was low. Consequently, we described healthcare utilization 
  108 
by subgroups but cannot make conclusive statements about similarities or differences by 
sex or race.  
 This study also has several strengths. Claims data contain little information on 
clinical characteristics, as their primary purpose is for reimbursement. In this study, data 
collected as part of the ARIC study exams were linked to CMS data and, consequently, 
information unavailable in claims data, such as detailed and validated demographic, 
behavioral and comorbid conditions measured using standardized methodology, were 
present and included in analyses. Second, prior research on AF did not study outpatient 
healthcare utilization.
30,213
 Furthermore, previous studies were conducted in a 
predominately white population
213
 or did not consider differences by sex or race.
30,213
 In 
response to the above gaps in the literature, we described overall healthcare utilization 
among participants with and without AF as well as sex- and race-specific utilization for 
both inpatient (MedPAR) and outpatient services.  
 In conclusion, this study provides evidence of the burden of AF healthcare 
utilization. The results highlight that AF is not just an electrical problem and treatment 
guidelines should incorporate assessment of overall cardiovascular risk and provide 
recommendations on comprehensive management of the patient. Participants with AF 
had greater underlying vascular disease and spent significantly more days hospitalized 
and seeking outpatient care than similar individuals without AF. The magnitude of the 
difference in utilization between those with and without AF was greatest for other-CVD-
related reasons and emphasizes the need to treat the underlying vascular disease in 
addition to rhythm or rate management among those with AF.  
  109 
11.6 TABLES 
 
Table 11.1: Characteristics of participants by atrial fibrillation status based on 
closest Atherosclerosis Risk in Communities Study exam preceding atrial 
fibrillation diagnosis or matching 
  
AF                                           
(n = 944) 
No AF                             
(n = 2,761) p-value 
Age at matching, years 73.5 ± 4.8 73.3 ± 4.6 0.23 
Women, % 43.9 45.2 0.46 
Black, % 13.9 14.3 0.74 
High school graduate, % 74.8 76.9 0.18 
Current smoker, % 19.2 13.5 <0.0001 
Current drinker, % 49.7 51.7 0.29 
BMI (kg/m
2
) 29.4 ± 5.7 28.3 ± 5.2 <0.0001 
Hypertension, % 59.9 48.8 <0.0001 
Antihypertensive medication, % 47.5 35.7 <0.0001 
Diabetes mellitus, % 21.3 16.4 0.001 
Total cholesterol, mg/dL 199.8 ± 37.4 203.9 ± 37.5 0.004 
LDL-c, mg/dL 124.0 ± 34.6 126.7 ± 34.3 0.04 
HDL-c, mg/dL 44.6 ± 18.1 46.0 ± 18.5 0.04 
Triglycerides, mg/dL 147.3 ± 83.4 144.9 ± 84.3 0.46 
Left ventricular hypertrophy, % 3.9 2.1 0.002 
Heart failure, % 10.4 3.8 <0.0001 
Coronary heart disease, % 18.9 9.4 <0.0001 
 
AF = atrial fibrillation 
BMI = body mass index 
Continuous variables presented as mean ± standard deviation (SD) 
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Table 11.2: Association of atrial fibrillation with inpatient (MedPAR) and 
outpatient healthcare utilization among Atherosclerosis Risk in Communities Study 
participants 
  AF (n = 944) No AF (n = 2,761) 
Follow up, years (mean ± SD) 4.1 ± 3.6 4.2 ± 3.6 
Inpatient (MedPAR) Utilization, days 
      Per person, median (IQR)
*
 10 (0 - 29) 0 (0 - 7) 
Unadjusted rate
†
 13.1 (11.5 - 15. 0) 2.8 (2.5 - 3.1) 
Unadjusted rate ratio 4.81 (4.00 - 5.78) Reference 
Rate ratio adjusted for matching criteria
ŧ
 4.80 (3.99 – 5.78) Reference 
Fully adjusted rate ratio
**
 3.85 (3.20 - 4.62) Reference 
Outpatient Utilization
§
  
      Per person, median (IQR)
 *
 122 (47 – 229.5) 50 (17 - 114) 
Unadjusted rate
†
 53.2 (50.4 - 56.1) 23.0 (22.2 - 23.8) 
Unadjusted rate ratio 2.33 (2.17 - 2.49) Reference 
Rate ratio adjusted for matching criteria
ŧ
 2.32 (2.16 - 2.48) Reference 
Fully adjusted rate ratio
**
 2.13 (1.99 - 2.28) Reference 
* During follow-up 
† Rate per year 
ŧ Adjusted for matching criteria: age (within 2 years), sex, race and field center 
** Adjusted for matching criteria and high school graduate, current smoking, current 
drinking, body mass index, hypertension, antihypertensive medication, diabetes mellitus, 
and prior heart failure and coronary heart disease 
§ Outpatient utilization defined as unique claims per date of service 
IQR = interquartile range 
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Table 11.3: Association of atrial fibrillation with inpatient (MedPAR) and outpatient healthcare utilization among 
Atherosclerosis Risk in Communities Study participants stratified by sex 
  Men Women 
  AF (n = 530) No AF (n = 1,512) AF (n = 414) No AF (n = 1,249) 
Follow up, years (mean ± SD) 4.1 ± 3.6 4.0 ± 3.5 4.0 ± 3.5 4.4 ± 3.7 
Inpatient (MedPAR) Utilization, days 
    Per person, median (IQR)
*
 9 (0 - 27) 0 (0 - 7) 10 (0 - 32) 0 (0 - 7) 
Unadjusted rate
†
 11.2 (9.5 - 13.4) 3.0 (2.6 - 3.5) 15.6 (12.8 - 19.0) 2.6 (2.2 - 3.0) 
Unadjusted rate ratio 3.82 (2.99 - 4.87) Reference 6.30 (4.77 - 8.32) Reference 
Rate ratio adjusted for matching criteria
ŧ
 3.57 (2.80 - 4.55) Reference 6.53 (4.92 - 8.67) Reference 
Fully adjusted rate ratio
**
 3.26 (2.56 - 4.15) Reference 4.75 (3.56 - 6.34) Reference 
Outpatient Utilization
§
  
  Per person, median (IQR)
*
 124 (48 - 241) 48 (17 - 113) 113 (40 - 223) 52 (15 - 116) 
Unadjusted rate
†
 52.8 (49.5 - 56.4) 23.9 (22.7 - 25.1) 54.6 (48.9 - 58.6) 21.9 (20.7 - 23.1) 
Unadjusted rate ratio 2.25 (2.04 - 2.44) Reference 2.45 (2.20 - 2.72) Reference 
Rate ratio adjusted for matching criteria
ŧ
 2.20 (2.01 - 2.40) Reference 2.45 (2.20 - 2.72) Reference 
Fully adjusted rate ratio
**
 2.04 (1.87 - 2.23) Reference 2.25 (2.02 - 2.51) Reference 
* During follow-up 
† Rate per year 
ŧ Adjusted for matching criteria: age (within 2 years), sex, race and field center 
** Adjusted for matching criteria and high school graduate, current smoking, current drinking, body mass index, hypertension, 
antihypertensive medication, diabetes mellitus, and prior heart failure and coronary heart disease 
§ Outpatient utilization defined as unique claims per date of service 
IQR = interquartile range 
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Table 11.4: Association of atrial fibrillation with inpatient (MedPAR) and outpatient healthcare utilization among 
Atherosclerosis Risk in Communities Study participants stratified by race 
  White Black 
  AF (n = 813) No AF (n = 2,366) AF (n = 131) No AF (n = 395) 
Follow up, years (mean ± SD) 4.2 ± 3.6 4.2 ± 3.6 3.5 ± 3.1 4.0 ± 3.6 
Inpatient (MedPAR) Utilization, days 
    Per person, median (IQR)
*
 10 (0 - 29) 0 (0 - 7) 7 (0 - 34) 0 (0 - 5) 
Unadjusted rate
†
 12.4 (10.8 - 14.3) 2.8 (2.5 - 3.1) 17.4 (11.9 - 25.6) 3.2 (2.3 - 4.4) 
Unadjusted rate ratio 4.66 (3.84 - 5.65) Reference 5.61 (3.18 - 9.88) Reference 
Rate ratio adjusted for matching criteria
ŧ
 4.65 (3.83 - 5.64) Reference 5.65 (3.20 - 9.97) Reference 
Fully adjusted rate ratio
**
 3.89 (3.21 - 4.72) Reference 3.74 (2.08 - 6.75) Reference 
Outpatient Utilization
§
  
  Per person, median (IQR)
*
 127 (49 - 236) 53 (18 - 118) 93 (32 - 175) 36 (8 - 97) 
Unadjusted rate
†
 53.1 (50.2 - 56.1) 23.3 (22.4 - 24.2) 53.7 (45.6 - 63.4) 21.0 (18. 6 - 23.7) 
Unadjusted rate ratio 2.29 (2.13 - 2.46) Reference 2.57 (2.05 - 3.23) Reference 
Rate ratio adjusted for matching criteria
ŧ
 2.27 (2.12 - 2.44) Reference 2.59 (2.07 - 3.26) Reference 
Fully adjusted rate ratio
**
 2.10 (1.95 - 2.25) Reference 2.34 (1.87 - 2.93) Reference 
* During follow-up 
† Rate per year 
ŧ Adjusted for matching criteria: age (within 2 years), sex, race and field center 
** Adjusted for matching criteria and high school graduate, current smoking, current drinking, body mass index, hypertension, 
antihypertensive medication, diabetes mellitus, and prior heart failure and coronary heart disease 
§ Outpatient utilization defined as unique claims per date of service 
IQR = interquartile range 
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Table 11.5: Primary reason for inpatient (MedPAR) and outpatient healthcare utilization stratified by atrial fibrillation status 
 
  
AF  
(n = 944) 
No AF  
(n = 2,761) 
Adjusted  
Rate Ratio
t
 
Inpatient (MedPAR) Utilization, days 
   Unadjusted rates
*
 
   AF related 0.5 (0.3 - 0.7) -- -- 
Other CVD related 4.3 (3.5 - 5.2) 0.8 (0.6 - 0.9) 4.76 (3.51 - 6.44) 
Non-CVD related 8.1 (7.0 - 9.4) 2.0 (1.8 - 2.3) 3.38 (2.76 - 4.15) 
Outpatient Utilization
§
  
  Unadjusted rates
*
 
   AF related 4.8 (4.3 - 5.4) 0.01 (0.01 - 0.02) -- 
Other CVD related 9.1 (8.4 - 9.7) 3.3 (3.1 - 3.5) 2.46 (2.24 - 2.70) 
Non-CVD related 38.7 (36.5 – 40.9) 19.5 (18.8 - 20.2) 1.85 (1.72 - 1.98) 
* Rates are days per year for inpatient (MedPAR) data and number of unique claims per date of service per year for outpatient claims 
t Adjusted for matching criteria and high school graduate, current smoking, current drinking, body mass index, hypertension, 
antihypertensive medication, diabetes mellitus, and prior heart failure and coronary heart disease 
§ Outpatient utilization defined as unique claims per date of service 
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Table 11.6: Primary reason for inpatient (MedPAR) and outpatient healthcare utilization stratified by atrial fibrillation status 
and sex 
 Men Women 
 
  
AF  
(n = 530) 
No AF  
(n = 1,512) 
Adjusted  
Rate Ratio
t
 
AF  
(n = 414) 
No AF  
(n = 1,249) 
Adjusted  
Rate Ratio
t
 
Inpatient (MedPAR) Utilization, days 
      Unadjusted rates
*
 
      
AF related 
0.6  
(0.4 - 1.1) 
-- -- 
0.3  
(0.2 - 0.5) 
-- -- 
Other CVD related 
2.7  
(2.1 - 3.4) 
1.1  
(0.8 - 1.3) 
2.41  
(1.67 - 3.47) 
6.6  
(4.8 - 9.1) 
0.5  
(0.3 - 0.6) 
11.94  
(7.08 - 20.13) 
Non-CVD related 
7.7  
(6.3 - 9.4) 
2.0  
(1.7 - 2.3) 
3.37  
(2.57 - 4.43) 
8.6  
(6.9 – 10.7) 
2.1  
(1.8 - 2.5) 
3.24  
(2.37 - 4.43) 
Outpatient Utilization
§
  
  Unadjusted rates
*
 
      
AF related 
4.7  
(4.1 - 5.4) 
-- -- 
5.0  
(4.2 - 5.9) 
-- -- 
Other CVD related 
8.9 
(8.2 - 9.7) 
3.7  
(3.4 - 4.0) 
2.18  
(1.93 - 2.46) 
9.2  
(8.1 - 10.4) 
2.9  
(2.7 - 3.1) 
2.88  
(2.49 - 3.33) 
Non-CVD related 
38.6  
(35.9 - 41.5) 
19.9  
(18.9 - 20.9) 
1.82  
(1.66 - 1.99) 
38.7  
(35.3 – 42.5) 
18.9  
(17.9 - 20.0) 
1.88  
(1.69 - 2.10) 
* Rates are days per year for inpatient (MedPAR) data and number of unique claims per date of service per year for outpatient claims 
t Adjusted for matching criteria and high school graduate, current smoking, current drinking, body mass index, hypertension, 
antihypertensive medication, diabetes mellitus, and prior heart failure and coronary heart disease 
§ Outpatient utilization defined as unique claims per date of service  
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Table 11.7: Descriptive analysis of the primary diagnosis codes for non-atrial fibrillation cardiovascular disease related 
hospitalizations stratified by atrial fibrillation status and sex 
 
 Men Women 
 AF  
(n=530) 
No AF  
(n=1,512) 
AF  
(n=414) 
No AF  
(n=1,249) 
 Number
*
 Rate
†
 Number Rate Number Rate Number Rate 
Total non-AF CVD-related hospitalizations 446 203.1 478 78.5 364 219.8 256 46.2 
Hypertensive disease (401 - 405) 14 6.4 15 2.5 26 15.7 12 2.2 
Myocardial infarction (410) 44 20.0 58 9.5 31 18.7 28 5.0 
Coronary atherosclerosis, native vessel (414.01) 62 28.2 90 14.8 35 21.1 30 5.4 
Heart failure (428) 99 45.1 51 8.4 98 59.2 31 5.6 
Cerebrovascular disease (430 - 438) 79 36.0 124 20.4 63 38.0 77 13.9 
† Unadjusted rates per 1,000 person-years 
Total person-years of follow up: Men with AF: 2,196, men without AF: 6,090, women with AF: 1,656 and women without AF: 5,54 
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Table 11.8: Association of atrial fibrillation with inpatient (MedPAR) and 
outpatient healthcare utilization among propensity score matched Atherosclerosis 
Risk in Communities Study participants 
  AF (n = 360) No AF (n = 360) 
Follow up, years (mean ± SD) 4.4 ± 3.7 4.1 ± 3.6 
Inpatient (MedPAR) Utilization, days 
      Per person, median (IQR)
*
 8 (0 - 26) 0 (0 - 6) 
Unadjusted rate
†
 9.4 (7.7 - 11.6) 2.1 (1.6 - 2.8) 
Unadjusted rate ratio 4.58 (3.30 - 6.36) Reference 
Rate ratio adjusted for matching criteria
ŧ
 4.57 (3.28 - 6.36) Reference 
Fully adjusted rate ratio
**
 4.90 (3.51 - 6.85) Reference 
Outpatient Utilization
§
  
      Per person, median (IQR)
*
 128 (48 - 220) 43 (13 - 113) 
Unadjusted rate
†
 47.8 (43.9 - 52.0) 21.9 (19.7 - 24.4) 
Unadjusted rate ratio 2.19 (1.92 - 2.51) Reference 
Rate ratio adjusted for matching criteria
ŧ
 2.18 (1.90 - 2.48) Reference 
Fully adjusted rate ratio
**
 2.19 (1.92 - 2.50) Reference 
* During follow-up 
† Rate per year 
ŧ Adjusted for matching criteria: age (within 2 years), sex, race, field center and 
propensity score 
** Adjusted for matching criteria and high school graduate, current smoking, current 
drinking, body mass index, hypertension, antihypertensive medication, diabetes mellitus, 
and prior heart failure and coronary heart disease 
§ Outpatient utilization defined as unique claims per date of service 
IQR = interquartile range 
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Table 11.9: Primary reason for inpatient (MedPAR) and outpatient healthcare utilization among propensity score matched 
Atherosclerosis Risk in Communities Study participants stratified by atrial fibrillation status 
  AF (n = 360) No AF (n = 360) 
Adjusted Rate 
Ratio
t
 
Inpatient (MedPAR) Utilization, days 
   Unadjusted rates
*
 
   AF related 0.2 (0.1 - 0.4) -- -- 
Other CVD related 2.7 (2.0 - 3.7) 0.5 (0.3 - 0.8) 6.30 (3.62 - 10.95) 
Non-CVD related 6.4 (5.1 - 8.2) 1.6 (1.2 - 2.2) 4.02 (2.76 - 5.85) 
Outpatient Utilization
§
  
   Unadjusted rates
*
 
   AF related 4.2 (3.5 - 5.0) -- -- 
Other CVD related 7.5 (6.7 - 8.4) 2.9 (2.5 - 3.4) 2.70 (2.26 - 3.24) 
Non-CVD related 35.7 (32.7 - 39.1) 19.0 (17.1 - 21.2) 1.87 (1.63 - 2.14) 
* Rates are days per year for inpatient (MedPAR) data and number of unique claims per date of service per year for outpatient claims 
t Adjusted for matching criteria and high school graduate, current smoking, current drinking, body mass index, hypertension, 
antihypertensive medication, diabetes mellitus, and prior heart failure and coronary heart disease 
§ Outpatient utilization defined as unique claims per date of service 
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11.7 FIGURES 
 
Figure 11.1: Derivation of study sample  
 
  119 
Figure 11.2: Rate ratio of days hospitalized per year stratified by sex and atrial 
fibrillation status 
 
Reference: Women without AF 
Diamonds represent rate ratios adjusted for matching criteria: age (within 2 years), sex, 
race and field center 
Squares represent rate ratios adjusted for matching criteria and high school graduate, 
current smoking, current drinking, body mass index, hypertension, antihypertensive 
medication, diabetes mellitus, and prior heart failure and coronary heart disease 
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12.0 SUMMARY 
 
 The primary aims of this dissertation were to assess temporal trends in the 
occurrence and prognosis of AF among acute MI patients, to determine the usefulness of 
administrative data to identify incident AF and to describe the impact of AF on healthcare 
utilization. 
The aims of the first manuscript were to address the lack of precision in trend 
analyses and the scarce data in nonwhite populations.
22,168
 In this large population-based 
sample, the prevalence of AF accompanying MI increased slightly over the 23-year study 
period, from 11% to 15%. Overall, co-occurrence of AF in the setting of MI was 
associated with an increased risk of death; the multivariable adjusted odds of 1-year 
mortality were 1.47 times greater (95% CI: 1.07 – 2.01) among MI patients with AF 
compared to those without AF. However, there was no evidence that the impact of AF on 
MI survival changed over time or differed over time by sex, race or MI classification. 
In the second manuscript the objectives were to address the limited knowledge 
regarding the usefulness of administrative data to determine AF incidence, the lack of 
inpatient and outpatient claims comparison, and the paucity of data in nonwhite 
populations.
180
 In this community-based prospective study, incidence rates of AF were 
slightly lower based on active ARIC follow-up compared to CMS surveillance; incidence 
rates per 1,000 person-years were 10.8 (95% CI: 10.1-11.6) and 13.6 (95% CI: 12.8-14.4) 
in ARIC and CMS, respectively. However, the rates by either method followed a similar 
pattern; they increased with age and were consistently higher among whites and men 
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compared to blacks and women, respectively. Concordance of incident AF between 
active ARIC follow-up and CMS surveillance was very good,
208
 with a Κ statistic of 0.77 
(95% CI: 0.75 – 0.80), although 19% more AF cases were identified from CMS largely 
due to outpatient AF ascertainment. Despite having to exclude 18,194 person-years of 
follow-up available to ARIC, out of 97,740 total person-years, because those participants 
were in Medicare Advantage plans and therefore had incomplete CMS claims, there was 
little bias in associations based exclusively on active ARIC follow-up versus surveillance 
including CMS.  
Due to the substantial and increasing burden of AF on healthcare utilization, the 
limited knowledge about inpatient and non-inpatient utilization, and the lack of sex- and 
race-specific data,
36,212,235
 the aims of the third manuscript were to heighten 
understanding of how AF patients utilize healthcare and to provide data that can be used 
to allocate adequate resources for the care of AF patients. In this sample of AF patients 
and matched controls from a community-based prospective study, rates of healthcare 
utilization, both inpatient and outpatient, were substantially higher among participants 
with AF compared to those matched with cases and without AF. The average numbers of 
days hospitalized per year were 13.1 (95% CI: 11.5-15.0) and 2.8 (95% CI: 2.5-3.1) for 
those with and without AF, respectively. The corresponding numbers of outpatient claims 
per year were 53.2 (95% CI: 50.4-56.1) and 23.0 (95% CI: 22.2-23.8) for those with and 
without AF, respectively. There was modest evidence of sex modifying the association 
between AF and inpatient utilization; AF was associated with higher inpatient utilization 
in women than in men. In both the inpatient and outpatient setting, healthcare utilization 
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was greatest for non-cardiovascular disease (CVD)-related reasons for those with as well 
as those without AF. However, the magnitude of the difference in utilization between 
those with and without AF was greatest for other-CVD-related reasons; for those with, 
compared to those without AF, the adjusted rate ratio for days hospitalized per year for 
other-CVD-related reasons was 4.76 (95% CI: 3.51 – 6.44) and for outpatient utilization 
the corresponding adjusted rate ratio was 2.46 (95% CI: 2.24 – 2.70).  
Each of these manuscripts contributed to the AF literature by addressing an 
important knowledge gap of public health significance. In the first study, the negative 
impact of AF on survival in the setting of MI persisted throughout the study, from 1987 
through 2009. Co-occurrence of AF in MI should be recognized as a critical clinical 
event. Currently, prognostic risk scores for MI do not consider AF in determining the risk 
of death and therapeutic decisions.
195,196
 Inclusion of AF in prognostic scores should be 
explored, especially because prevalence of AF in the community is estimated to increase 
as the population ages,
2,3
 and because AF often complicates MI.
23,166
 Furthermore, the 
optimal treatment strategy is unresolved when the risks of thromboembolism and 
bleeding are considered
197,198
 and new oral anticoagulant agents raise additional questions 
about the optimal treatment strategy.
199,200
 In the second study, two very different 
methods to identifying incident AF produced similar results with comparable incidence 
rates, high concordance, and little evidence of bias of associations between AF and risk 
factors. The ability to identify incident AF events is particularly important for studies of 
healthcare utilization over the entire disease course of AF, comparative effectiveness 
research, and drug safety surveillance. This study provides support for the potential value 
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of utilizing multiple data sources to identify incident AF and suggests the need for 
caution about completeness of each data source. Each approach has unique strengths and 
limitations and, collectively, could provide a more complete picture of newly-diagnosed 
AF. Moving forward, ARIC and similar studies should evaluate how to incorporate 
Medicare and other administrative data in the ascertainment of outcomes, factoring in the 
data limitations regarding coverage and quality. In the third study, the substantially 
greater healthcare utilization (inpatient and outpatient) among those with AF, especially 
the differential utilization due to other-CVD-related reasons, highlighted the need for AF 
treatment to address the accompanying cardiovascular comorbidities in addition to rate or 
rhythm treatment. Treatment guidelines should incorporate assessment of overall 
cardiovascular risk and provide recommendations on comprehensive management of the 
patient.  
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14.0 APPENDIX: DICTIONARY OF ABBREVIATIONS 
 
ACME  Automated Classification of Medical Entities  
AF  atrial fibrillation  
AFL  atrial flutter 
ARIC  Atherosclerosis Risk in Communities  
AV  antrioventricular 
BMI  body mass index 
BPM  beats per minute 
CHD  coronary heart disease 
CHS  Cardiovascular Health Study 
CI  confidence interval 
CK  creatinine phosphokinase 
CMS  Centers for Medicare and Medicaid Services 
CPAP  continuous positive airway pressure 
CRP  C-reactive protein 
CVD  cardiovascular disease 
ECG  electrocardiogram 
FEV1  forced expiratory volume in one second 
FFS  fee-for-service 
FHS  Framingham Heart Study 
HF  heart failure 
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HMO  health maintenance organization 
HR  hazard ratio 
ICD  implantable cardiac defibrillator 
ICD-9  International Classification of Diseases, 9
th
 revision 
ICD-10 International Classification of Diseases, 10
th
 revision 
IQR  interquartile range  
Κ  Kappa statistic 
LOS  length of stay 
MedPAR Medicare Provider Analysis and Review 
MI  acute myocardial infarction 
NSTEMI non-ST-Elevation myocardial infarction 
OR  odds ratio 
OSA  obstructive sleep apnea 
PDE  Prescription Drug Event 
PPV  positive predictive value 
PREDICT Predicting Risk of Death in Cardiac Disease Tool 
PUFA  polyunsaturated fatty acid 
SNPs  single-nucleotide polymorphisms 
STEMI ST-Elevation myocardial infarction 
US  United States 
WHS  Women’s Health Study 
 
